var docs;if (!docs) docs =[]; docs["70"]={"7001":"<p><b>Title</b> Cobicistat / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobicistat-containing products and carbamazepine due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance. Concomitant use with carbamazepine is listed as a contraindication most cobicistat product labels.</p> \n<p><b>Discussion</b> The carbamazepine AUC was an average of 43% higher, and the AUC of the active metabolite carbamazepine 10,11-epoxide was an average of 35% lower, with concurrent elvitegravir and cobicistat in a study of 12 subjects who received carbamazepine 200 mg twice/day with elvitegravir 150 mg/day and cobicistat 150 mg/day.<sup>1</sup> <br><br>The prescribing information for several cobicistat-containing products contraindicates use with carbamazepine due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3,4</sup> Labeling for cobicistat/darunavir recommends consideration of alternative antiepileptics when possible, but does not list carbamazepine use as contraindicated.<sup>5</sup><br><br>The likely mechanism for this observed increase in carbamazepine concentrations is inhibition of the CYP3A-mediated metabolism of carbamazepine by cobicistat.<sup>1</sup> Carbamazepine may also enhance the metabolism of cobicistat, which is used in combination with various antivirals in order to inhibit their metabolism and increase their serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2015.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015. </p>\n<p>4. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2016.</p>\n<p>5. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7002":"<p><b>Title</b> Cobicistat / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider an alternative antiepileptic when possible in patients treated with cobicistat-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk of viral resistance. The Canadian labeling for atazanavir/cobicistat states that concurrent use with oxcarbazepine is not recommended.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with oxcarbazepine are not available, US prescribing information for cobicistat-containing products recommends use of an alternative antiepileptic when possible due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.<sup>1,2,3,4</sup> The Canadian labeling for atazanavir/cobicistat states that concurrent use with oxcarbazepine is not recommended.<sup>5</sup><br><br>The likely mechanism for this predicted interaction is oxcarbazepine induction of the CYP3A-mediated metabolism of cobicistat, which is used in combination with antiviral agents to increase their systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. Evotaz (atazanavir/cobicistat) [prescribing information]. Montreal, Canada: Bristol-Myers Squibb Canada; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7003":"<p><b>Title</b> Cobicistat / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobicistat-containing products and fosphenytoin/phenytoin when possible due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance. Concomitant use with phenytoin is listed as a contraindication in most cobicistat product labels.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Although specific data for cobicistat with fosphenytoin/phenytoin are not available, the prescribing information for several cobicistat-containing products lists concomitant use with phenytoin as contraindicated due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3,4</sup> Labeling for cobicistat/darunavir recommends consideration of alternative antiepileptics when possible, but does not list phenytoin use as contraindicated.<sup>5</sup><br><br>The likely mechanism for this predicted interaction is phenytoin induction of the CYP3A-mediated metabolism of cobicistat, which is used in combination with antiviral agents to increase their systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2015.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015. </p>\n<p>4. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p>5. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7004":"<p><b>Title</b> Cobicistat / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobicistat-containing products and phenobarbital when possible due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance. Concomitant use with phenobarbital is listed as a contraindication in most cobicistat product labels.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with phenobarbital are not available, the prescribing information for most cobicistat-containing products lists concomitant use with phenobarbital as contraindicated due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3,4</sup> Labeling for cobicistat/darunavir recommends consideration of alternative antiepileptics when possible, but does not list phenobarbital use as contraindicated.<sup>5</sup><br><br>The likely mechanism for this predicted interaction is phenobarbital induction of the CYP3A-mediated metabolism of cobicistat, which is used in combination with antiviral agents to increase their systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2015.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015. </p>\n<p>4. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p>5. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7005":"<p><b>Title</b> Elvitegravir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of carbamazepine with elvitegravir/cobicistat/emtricitabine/tenofovir combination products is contraindicated, and concurrent use of carbamazepine with the single-entity elvitegravir product is not recommended.</p> \n<p><b>Discussion</b> The elvitegravir AUC and minimum serum concentration (Cmin) were an average of 69% and 97% lower, respectively, with concurrent carbamazepine in a study of 12 subjects who received carbamazepine 200 mg twice/day with elvitegravir 150 mg/day and cobicistat 150 mg/day.<sup>1</sup> Additionally, the carbamazepine AUC was an average of 43% higher and the AUC of the active metabolite carbamazepine 10,11-epoxide was an average of 35% lower with use of this combination. The prescribing information for elvitegravir products contraindicates or does not recommend use with carbamazepine (or phenytoin or phenobarbital) due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3</sup><br><br>The likely mechanism for this predicted interaction is carbamazepine induction of the CYP3A-mediated metabolism of elvitegravir.<sup>1</sup> Carbamazepine may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations. The increased carbamazepine concentration is likely due to cobicistat inhibition of carbamazepine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7006":"<p><b>Title</b> Elvitegravir / OXcarbazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: With the single-agent elvitegravir product, use of oxcarbazepine should be avoided. With elvitegravir/cobicistat/emtricitabine/tenofovir combination products, consider using an alternative antiepileptic.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of single-agent elvitegravir (which is used with a ritonavir-boosted protease inhibitor) with oxcarbazepine is not recommended. Consider using an alternative antiepileptic when possible in patients who are being treated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products due to the potential for decreased antiviral concentrations/effectiveness and the associated increased risk for viral resistance to these agents.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus oxcarbazepine are not available, the prescribing information for the single-entity elvitegravir product (which is used with a ritonavir-boosted protease inhibitor) cautions that concurrent use with oxcarbazepine is not recommended.<sup>1</sup> Additionally, the prescribing information for elvitegravir/cobicistat/emtricitabine/tenofovir combination products recommends using an alternative antiepileptic when possible due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>2,3</sup><br><br>The likely mechanism for this predicted interaction is oxcarbazepine induction of the CYP3A-mediated metabolism of elvitegravir.<sup>1,2</sup> Oxcarbazepine may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7007":"<p><b>Title</b> Elvitegravir / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of fosphenytoin-phenytoin with elvitegravir/cobicistat/emtricitabine/tenofovir combination products is contraindicated, and concurrent use of fosphenytoin-phenytoin with the single-entity elvitegravir product is not recommended.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Although specific data for elvitegravir plus phenytoin are not available, the prescribing information for elvitegravir products contraindicates or does not recommend use with phenytoin (or carbamazepine or phenobarbital) due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3</sup> The elvitegravir AUC and minimum serum concentration (Cmin) were an average of 69% and 97% lower, respectively, with concurrent carbamazepine in a study of 12 subjects who received carbamazepine 200 mg twice/day with elvitegravir 150 mg/day and cobicistat 150 mg/day.<sup>1</sup> Additionally, the carbamazepine AUC was an average of 43% higher and the AUC of the active metabolite carbamazepine 10,11-epoxide was an average of 35% lower with use of this combination.<br><br>The likely mechanism for this predicted interaction is phenytoin induction of the CYP3A-mediated metabolism of elvitegravir.<sup>1</sup> Phenytoin may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations. The increased carbamazepine concentration is likely due to cobicistat inhibition of carbamazepine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7008":"<p><b>Title</b> Elvitegravir / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of phenobarbital with the elvitegravir/cobicistat/emtricitabine/tenofovir combination products is contraindicated, and concurrent use of phenobarbital with the single-entity elvitegravir product is not recommended.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus phenobarbital are not available, the prescribing information for elvitegravir products contraindicates or does not recommend use with phenobarbital (or phenytoin or carbamazepine) due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3</sup> The elvitegravir AUC and minimum serum concentration (Cmin) were an average of 69% and 97% lower, respectively, with concurrent carbamazepine in a study of 12 subjects who received carbamazepine 200 mg twice/day with elvitegravir 150 mg/day and cobicistat 150 mg/day.<sup>1</sup> Additionally, the carbamazepine AUC was an average of 43% higher and the AUC of the active metabolite carbamazepine 10,11-epoxide was an average of 35% lower with use of this combination.<br><br>The likely mechanism for this predicted interaction is phenobarbital induction of the CYP3A-mediated metabolism of elvitegravir.<sup>1</sup> Phenobarbital may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations. The increased carbamazepine concentration is likely due to cobicistat inhibition of carbamazepine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7009":"<p><b>Title</b> Ethosuximide / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Ethosuximide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of ethosuximide and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product due to the potential for increased ethosuximide concentrations and related toxicities. Monitor patients closely for signs and symptoms of ethosuximide adverse effects.</p> \n<p><b>Discussion</b> US prescribing information for the elvitegravir/cobicistat/emtricitabine/tenofovir combination product states that use with ethosuximide may be associated with increased concentrations of ethosuximide, although no specific data are provided.<sup>1</sup> Caution and increased monitoring are recommended.<br><br>The exact mechanism(s) for this potential interaction is(are) unclear; however, inhibition of ethosuximide metabolism by cobicistat is a likely mechanism. Cobicistat is a strong inhibitor of CYP3A,<sup>1</sup> and ethosuximide may be at least partially dependent on CYP3A for its metabolism.<sup>2,3</sup> US prescribing information for other cobicistat-containing products describes the potential for these products to inhibit CYP3A, but does not specifically include ethosuximide as a potential interacting agent.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. Giaccone M, Bartoli A, Gatti G, et al. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. <i>Br J Clin Pharmacol</i>. 1996;41(6):575-579. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8799524\">[PubMed 8799524]</a></p>\n<p>3. Bachmann K, Chu CA, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. <i>Pharmacology</i>. 1992;45(3):121-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1438522\">[PubMed 1438522]</a></p>\n<p>4. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>5. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>6. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7010":"<p><b>Title</b> ClonazePAM / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of ClonazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of clonazepam and cobicistat-containing products due to the potential for increased clonazepam concentrations and related toxicities. Monitor patients closely for signs and symptoms of clonazepam adverse effects.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with clonazepam may be associated with increased concentrations of clonazepam, although no specific data are provided.<sup>1,2,3,4</sup> Caution and increased monitoring are recommended.<br><br>The suspected primary mechanism of this interaction is cobicistat inhibition of CYP3A-mediated clonazepam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7014":"<p><b>Title</b> Elvitegravir / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with an elvitegravir-containing product. Patients receiving such a combination should be monitored closely for evidence of ketoconazole and/or elvitegravir toxicity.</p> \n<p><b>Discussion</b> The average elvitegravir AUC was 48% higher with concurrent ketoconazole in a study of 18 subjects who received ketoconazole 200 mg twice/day together with elvitegravir/ritonavir (150 mg/100 mg once/day).<sup>1,2,3</sup> The elvitegravir maximum serum concentration (Cmax) and minimum serum concentration (Cmin) were also an average of 17% and 67% higher with concurrent ketoconazole. The specific mechanism for this observed interaction is ketoconazole-mediated inhibition of elvitegravir metabolism and/or elimination.<br><br>In addition, US prescribing information for elvitegravir-containing products cautions that concentrations of ketoconazole may be increased, leading to recommendations that the ketoconazole dose be limited to 200 mg/day.<sup>1,2,3</sup> Though specific data to support this recommendation are not provided, it is unclear whether the interaction is due to elvitegravir itself or to drugs given in combination with elvitegravir (i.e., ritonavir-boosted protease inhibitor or cobicistat).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7015":"<p><b>Title</b> Elvitegravir / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with elvitegravir-containing products. Patients receiving these combinations should be monitored particularly closely for evidence of itraconazole and/or elvitegravir toxicity.</p> \n<p><b>Discussion</b> Though specific data on this combination are not available, data with the azole antifungal ketoconazole, which is a similarly strong CYP3A inhibitor support the existence of an interaction. The average elvitegravir AUC was 48% higher with concurrent ketoconazole in a study of 18 subjects who received ketoconazole 200 mg twice/day together with elvitegravir/ritonavir (150 mg /100 mg once/day).<sup>1</sup> The elvitegravir maximum serum concentration (Cmax) and minimum serum concentration (Cmin) were also an average of 17% and 67% higher with concurrent ketoconazole. The likely mechanism for this observed interaction is ketoconazole-mediated inhibition of elvitegravir metabolism and/or elimination; itraconazole would be expected to interact in a similar manner.<br><br>In addition, the prescribing information for elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination products cautions that concentrations of itraconazole may be increased, leading to recommendations that the itraconazole dose be limited to 200 mg/day.<sup>1,2</sup> Though specific data to support this recommendation are not provided, this interaction is likely due to the cobicistat component as cobicistat is strong inhibitor of CYP3A, CYP2D6, and several drug transporters. Similar recommendations apply to ritonavir, which is coadministered with single-agent elvitegravir.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7016":"<p><b>Title</b> Elvitegravir / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products. Similar recommendations apply to low-dose ritonavir, which is given in combination with single-dose elvitegravir. Patients who receive these combinations should be monitored particularly closely for evidence of voriconazole and/or elvitegravir toxicity.</p> \n<p><b>Discussion</b> Though specific data on this combination are not available, data with the azole antifungal ketoconazole, which is a similarly strong CYP3A inhibitor support the existence of an interaction. The average elvitegravir AUC was 48% higher with concurrent ketoconazole in a study of 18 subjects who received ketoconazole 200 mg twice/day together with elvitegravir/ritonavir (150 mg /100 mg once/day).<sup>1</sup> The elvitegravir maximum serum concentration (Cmax) and minimum serum concentration (Cmin) were also an average of 17% and 67% higher with concurrent ketoconazole. The likely mechanism for this observed interaction is ketoconazole-mediated inhibition of elvitegravir metabolism and/or elimination; itraconazole would be expected to interact in a similar manner.<br><br>In addition, the prescribing information for elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination products cautions that concentrations of voriconazole may be increased, leading to recommendations that the risk/benefit ratio concerning voriconazole use be carefully considered prior to its use.<sup>1,2</sup> Though specific data to support this recommendation are not provided, this interaction is likely due to the cobicistat component as cobicistat is strong inhibitor of CYP3A, CYP2D6, and several drug transporters. Although no recommendations are offered for use of single-agent elvitegravir with voriconazole,<sup>3</sup> similar recommendations for careful risk/benefit assessment apply to the use of low-dose ritonavir (which is given with single-agent elvitegravir) with voriconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7017":"<p><b>Title</b> Ketoconazole (Systemic) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit ketoconazole to a maximum adult dose of 200 mg/day in patients being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product. Dosing recommendations for use with other cobicistat-containing products are not available. Patients receiving this combination should be monitored closely for evidence of ketoconazole and cobicistat toxicity.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with ketoconazole may be associated with increased concentrations of cobicistat and/or ketoconazole, although no specific data are provided.<sup>1,2,3,4</sup> The suspected primary mechanism of this interaction is mutual inhibition of CYP3A mediated metabolism of cobicistat and ketoconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7018":"<p><b>Title</b> Itraconazole / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit itraconazole to a maximum adult dose of 200 mg/day in patients being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product. Dosing recommendations for use with other cobicistat-containing products are not available. Patients receiving this combination should be monitored closely for evidence of itraconazole and cobicistat toxicity.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with itraconazole may be associated with increased concentrations of cobicistat and/or itraconazole, although no specific data are provided.<sup>1,2,3,4</sup> The suspected primary mechanism of this interaction is mutual inhibition of CYP3A mediated metabolism of cobicistat and itraconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7019":"<p><b>Title</b> Voriconazole / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Voriconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients being treated with cobicistat-containing products. Patients who receive this combination should be monitored particularly closely for evidence of voriconazole and cobicistat toxicity.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that use with voriconazole may be associated with increased concentrations of cobicistat and/or voriconazole, although no specific data are provided.<sup>1,2,3,4</sup> The mechanisms of this possible mutual interaction have not been investigated. Voriconazole may increase cobicistat exposure via inhibition of its CYP3A-mediated metabolism. Cobicistat may increase voriconazole exposure via inhibition of its metabolism or active transport, although the specific enzymes and/or transporters likely to be involved have not been identified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7022":"<p><b>Title</b> Cobicistat / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifapentine is not recommended with darunavir/cobicistat or elvitegravir/cobicistat/emtricitabine/tenofovir due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance. While no specific recommendations are provided for rifapentine coadministration with atazanavir and cobicistat, seek alternatives to this combination when possible.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with rifapentine are not available, rifapentine is not recommended with darunavir/cobicistat or elvitegravir/cobicistat/emtricitabine/tenofovir due to the potential for decreased antiviral concentrations and the associated increased risk for viral resistance.<sup>1,2</sup><br><br>The likely mechanism for this predicted interaction is rifapentine induction of the CYP3A-mediated metabolism of cobicistat, which is used to boost exposure to coadministered antiviral agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7023":"<p><b>Title</b> Rifabutin / Elvitegravir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: Use of the Stribild brand combination product should be avoided, while use of the Vitekta brand (which is to be used with a ritonavir-boosted protease inhibitor) can be used with a substantial reduction in rifabutin dose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Elvitegravir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When elvitegravir is being used in combination with a ritonavir-boosted protease inhibitor, concurrent use of rifabutin requires a reduction in the rifabutin dose of at least 75% of the usual (300 mg/day) dose, meaning a reduction to 150 mg every other day or three times a week (or less). Any use of this combination should also be done with increased monitoring of rifabutin response and toxicity. Use of elvitegravir/cobicistat/emtricitabine/tenofovir combination products with rifabutin is not recommended.</p> \n<p><b>Discussion</b> Rifabutin concentrations were not significantly altered with concurrent use of either elvitegravir/ritonavir or elvitegravir/cobicistat in two separate studies summarized in US prescribing information.<sup>1,2</sup> However, concentrations of the active metabolite 25-O-desacetyl-rifabutin were significantly increased, with the AUC 9.5- and 6.25-fold higher with concurrent use of lower-dose rifabutin (150 mg every other day) and elvitegravir/ritonavir (300 mg/100 mg once daily) or elvitegravir/cobicistat (150 mg/150 mg once daily), respectively. The elvitegravir AUC and minimum serum concentration were 21% and 67% lower, respectively, with use of this lower-dose rifabutin, while elvitegravir concentrations were not significantly altered when elvitegravir/ritonavir was combined with low-dose rifabutin.<sup>1,2</sup><br><br>Based on these data, the prescribing information for elvitegravir alone (which is used with a ritonavir-boosted protease inhibitor) recommends substantial rifabutin dose reductions if the combination is to be used,<sup>1</sup> and prescribing information for elvitegravir/cobicistat/emtricitabine/tenofovir combination products cautions that use with rifabutin is not recommended.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2015.</p>\n<p>2. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7024":"<p><b>Title</b> Elvitegravir / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifapentine is not recommended with elvitegravir-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus rifapentine are not available, elvitegravir AUC and minimum serum concentration (Cmin) were an average of 21% and 67% lower, respectively, when elvitegravir (150 mg/day) and cobicistat (150 mg/day) were given with rifabutin (150 mg every other day),<sup>1,2,3</sup> which is a rifamycin derivative that is an enzyme/transporter inducer generally considered somewhat more potent or of equivalent potency to rifapentine. Given these findings, a similar interaction would be expected with rifapentine. Use of rifapentine is not recommended with elvitegravir-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3</sup><br><br>The likely mechanism for this predicted interaction is rifapentine induction of the CYP3A-mediated metabolism of elvitegravir. Rifapentine may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7025":"<p><b>Title</b> Elvitegravir / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider using an alternative corticosteroid in patients who are being treated with elvitegravir-containing products. Use in combination may increase the potential for decreased antiviral concentrations and effectiveness and may increase the risk for viral resistance. Monitor patients receiving these agents in combination for diminished antiviral response.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus dexamethasone are not available, US prescribing information for elvitegravir-containing products cautions that an alternative corticosteroid should be considered for patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.<sup>1</sup> Concurrent use of systemic dexamethasone may decrease antiviral concentrations and effectiveness and may potentially increase the risk for viral resistance to these agents.<br><br>The likely mechanism for this predicted interaction is dexamethasone induction of the CYP3A-mediated metabolism of elvitegravir.<sup>1</sup> Dexamethasone may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7026":"<p><b>Title</b> Cobicistat / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Cobicistat. Dexamethasone (Systemic) may also counteract the boosting effects of Cobicistat on some agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider an alternative corticosteroid in patients treated with cobicistat-containing regimens. Concomitant dexamethasone use may decrease antiviral concentrations and effectiveness and may increase the risk for viral resistance. Patients who require concurrent use of systemic dexamethasone should be monitored closely for evidence of diminished antiviral response.</p> \n<p><b>Discussion</b> Although no specific data are available, US prescribing information recommends that corticosteroids other than dexamethasone should be considered in patients receiving cobicistat-containing products.<sup>1,2,3,4</sup> Concurrent use of systemic dexamethasone may decrease cobicistat concentrations and effectiveness and may increase the risk for viral resistance to the antiviral agents used with cobicistat.<br><br>The likely mechanism for this predicted interaction is dexamethasone induction of the CYP3A-mediated metabolism of cobicistat, which is used to boost serum concentrations of other agents.<sup>1,2,3,4</sup> Dexamethasone may also increase the rate of metabolism of boosted agents (eg, elvitegravir, atazanavir).</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7028":"<p><b>Title</b> Fluticasone (Oral Inhalation) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Fluticasone (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of orally inhaled fluticasone with a strong CYP3A inhibitor such as cobicistat is not recommended. Use an alternative inhaled corticosteroid when possible, particularly for potentially longer-term concurrent use.</p> \n<p><b>Discussion</b> Although specific data for cobicistat use with fluticasone are not available, US prescribing information for cobicistat-containing products recommends use of an alternative corticosteroid when possible, especially for long-term concurrent use, due to the potential for increased fluticasone concentrations and adrenal suppression with combined use.<sup>1,2,3,4</sup><br><br>Fluticasone oral inhalation US prescribing information does not recommend concurrent use of a strong CYP3A4 inhibitor such as cobicistat due to evidence that concurrent use is associated with increases in plasma fluticasone exposure and decreases in plasma cortisol concentrations.<sup>5</sup> A study with orally inhaled fluticasone (1000 mcg) and the strong CYP3A4 inhibitor ketoconazole (200 mg/day) found an average 1.9-fold increase in fluticasone AUC and an average 45% decrease in plasma cortisol concentrations (N=8 healthy volunteers).<sup>2</sup> Fluticasone average AUC increased more than 100-fold with concurrent use of fluticasone nasal inhalation (200 mcg/day) and the strong CYP3A4 inhibitor ritonavir (100 mg twice daily) in a study of 18 healthy volunteers.<sup>2</sup> This combination was also associated with an average 86% decrease in plasma cortisol concentrations. A study with the moderate CYP3A4 inhibitor erythromycin (333 mg three times/day) and orally inhaled fluticasone (500 mcg twice/day) found no significant change in fluticasone concentrations.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is cobicistat inhibition of CYP3A mediated fluticasone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>Flovent</i> (fluticasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7030":"<p><b>Title</b> Tadalafil / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Management of this interaction varies according to indication for tadalafil (i.e., whether used to treat erectile dysfunction, pulmonary arterial hypertension, or benign prostatic hypertrophy).</p></li>\n <li><p><b>International labeling</b>: Recommendations regarding management of this interaction may vary according to US versus Canadian tadalafil labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Tadalafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors (eg, cobicistat) may vary based on indication and/or international labeling. <u>For treatment of erectile dysfunction</u> in patients also receiving strong CYP3A4 inhibitors, tadalafil US product labeling recommends limiting tadalafil to a maximum of 2.5 mg/day (for once daily use) or 10 mg per 72 hours (for use as needed). The Canadian product labeling recommends a tadalafil dose of 2.5 to 5 mg/day (for once daily use), or 10 mg at minimum intervals of 48 hours and maximum of 3 doses/week, with the option of increasing tadalafil to 20 mg if the lower dose is tolerated but ineffective (for use as needed). <u>For treatment of pulmonary arterial hypertension</u>, the tadalafil US prescribing information recommends avoiding concurrent use in patients who are also taking a strong CYP3A4 inhibitor. In contrast, US prescribing information for cobicistat-containing products recommends initiating tadalafil for pulmonary arterial hypertension after at least 1 week of a cobicistat regimen and at a dose of 20 mg, increasing to a maximum of 40 mg/day as tolerated. Tadalafil should be stopped at least 24 hours before initiation of a cobicistat-containing product. However, patients switching from ritonavir to cobicistat without other changes can maintain their previous tadalafil dose.</p> \n<p><b>Discussion</b> Tadalafil dosing changes will likely be needed with concurrent use of cobicistat-containing products, and recommended changes vary by country (US vs Canada) and tadalafil indication.<sup>1,2,3,4,5,6,7</sup> An interaction between these agents is predicted based on the ability of cobicistat to inhibit CYP3A mediated tadalafil metabolism.<br><br>The average tadalafil AUC increased 312%, and mean tadalafil maximum serum concentration (Cmax) increased 22%, when a single tadalafil 20 mg dose was given with the strong CYP3A4 inhibitor ketoconazole (400 mg daily), as compared with tadalafil alone.<sup>5,7</sup> In another study, the average tadalafil AUC and Cmax were 107% and 15% higher, respectively, when tadalafil (10 mg single dose) was administered with ketoconazole (200 mg daily).<sup>2,4</sup> A published case report also describes priapism lasting more than 4 hours in a patient who took a single tadalafil 10 mg dose shortly after beginning treatment with the strong CYP3A4 inhibitor itraconazole.<sup>8</sup> Priapism recurred approximately 1 month later following a single tadalafil dose, while the patient was still taking itraconazole; however, both preceding and following these events, the patient was able to take sildenafil (100 mg single doses) with concurrent itraconazole without adverse effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>Cialis</i> (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2011.</p>\n<p>6. <i>Cialis</i> (tadalafil) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; March 2009.</p>\n<p>7. <i>Adcirca</i> (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2011.</p>\n<p>8. Galatti L, Fioravanti A, Salvo F, Polimeni G, Giustini SE. Interaction between tadalafil and itraconazole. <i>Ann Pharmacother</i>. 2005;39(1):200. [PubMed: 15572599]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7031":"<p><b>Title</b> Vardenafil / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Use of the vardenafil orally disintegrating tablet with strong CYP3A inhibitors (eg, cobicistat) is contraindicated.</p></li>\n <li><p><b>International labeling</b>: US and Canadian recommendations differ on the use of strong CYP3A inhibitors such as cobicistat with the Levitra brand of vardenafil.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Vardenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations regarding the management of this interaction vary by vardenafil product and by country. For the Levitra brand of vardenafil (or equivalent), limit the dose of vardenafil to 2.5 mg per 72-hour period with concurrent use of cobicistat-containing products. This recommendation conflicts with Canadian labeling for Levitra brand vardenafil, which contraindicates concurrent use with any strong CYP3A inhibitor such as cobicistat. Use of the Staxyn brand (or equivalent) of vardenafil with a strong CYP3A4 inhibitor such as cobicistat is contraindicated according to both US and Canadian labeling.</p> \n<p><b>Discussion</b> Vardenafil dosing changes will likely be needed with any concurrent use of cobicistat, and the specific changes recommended vary by product and by country (US vs Canada).<sup>1,2,3,4,5,6,7,8</sup> This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of vardenafil.<br><br>The average vardenafil AUC was 49-fold higher with concurrent ritonavir (600 mg twice/day), 16-fold higher with concurrent indinavir (800 mg three times daily), and 10-fold higher with ketoconazole (200 mg daily).<sup>5,6,7,8</sup> Average vardenafil maximum serum concentration was 4- to 13-fold higher with all of these strong CYP3A4 inhibitors (note that the 200 mg/day ketoconazole dose is treated as a more “moderate” CYP3A4 inhibitor by the vardenafil prescribing information). With the moderate CYP3A4 inhibitor erythromycin (500 mg three times daily), the average vardenafil AUC was 4-fold higher.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>Levitra</i> (vardenafil) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; April 2011.</p>\n<p>6. <i>Staxyn</i> (vardenafil) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; August 2010.</p>\n<p>7. <i>Staxyn</i> (vardenafil) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; August 2011.</p>\n<p>8. <i>Levitra</i> (vardenafil) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7032":"<p><b>Title</b> Bosentan / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Bosentan. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> For patients who have been receiving cobicistat-containing products for at least 10 days, initiate bosentan at 62.5 mg once daily or every other day. For patients receiving bosentan and initiating cobicistat-containing regimens, discontinue bosentan at least 36 hours before cobicistat initiation and wait a minimum of 10 days before restarting bosentan (at dose of 62.5 mg once daily or every other day, based on tolerability). For patients receiving bosentan and switching from ritonavir to cobicistat without other changes (eg, from an atazanavir/ritonavir regimen to an atazanavir/cobicistat regimen), maintain the previous bosentan dose. All patients receiving this combination should be monitored closely for evidence of bosentan adverse effects.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with bosentan may result in elevated bosentan serum concentrations.<sup>1,2,3,4</sup> No specific pharmacokinetic data are reported. The suspected mechanism of this interaction is cobicistat inhibition of OATP1B1 and OATP1B3, which are responsible for the hepatic uptake of bosentan.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the ommon mechanism of ts nteractions with cyclosporin A, rifampicin, and sildenafil. <i>Drug Metab Dispos</i>. 2007;35(8):1400-1407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17496208\">[PubMed 17496208]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7034":"<p><b>Title</b> Phenytoin / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Applies to the intramuscular depot formulation</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with phenytoin. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with phenytoin may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7035":"<p><b>Title</b> DiazePAM / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Applies to the intramuscular depot formulation</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with diazepam. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with diazepam may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7036":"<p><b>Title</b> ClonazePAM / Cosyntropin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of ClonazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with clonazepam. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with clonazepam may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7037":"<p><b>Title</b> Nitrazepam / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Applies to the intramuscular depot formulation</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of Nitrazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with nitrazepam. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with nitrazepam may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7038":"<p><b>Title</b> PHENobarbital / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Applies to the intramuscular depot formulation</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with phenobarbital. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with phenobarbital may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7039":"<p><b>Title</b> Primidone / Cosyntropin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Applies to the intramuscular depot formulation</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cosyntropin may enhance the hepatotoxic effect of Primidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for hepatoxicity in patients receiving intramuscular (IM) depot cosyntropin concomitantly with primidone. Cosyntropin treatment should be administered at the lowest effective dose and for the shortest duration of time necessary.</p> \n<p><b>Discussion</b> Synacthen Depot (cosyntropin) Canadian product monograph suggests that concomitant use with primidone may put patients at an increased risk for hepatotoxicity.<sup>1</sup> A specific mechanism is not described however. The depot is approved for diagnostic and therapeutic use in Canada.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Synacthen Depot (cosyntropin). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7040":"<p><b>Title</b> AtorvaSTATin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Initiate atorvastatin at the lowest recommended dose and titrate slowly as needed while monitoring closely for evidence of atorvastatin toxicity. Atorvastatin dose should not exceed 20 mg/day with concurrent use of darunavir and cobicistat.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (150 mg/150 mg/200 mg/10 mg daily) increased the atorvastatin (10 mg single dose) AUC and maximum serum concentration 2.6-fold and 2.3-fold, respectively.<sup>1</sup> <br><br>US prescribing information for cobicistat-containing products recommends initiation of concomitant atorvastatin at the lowest recommended dose and monitoring for atorvastatin safety.<sup>1,2,3,4,5</sup> The mechanism of interaction between these agents has not been investigated, but may include cobicistat inhibition of atorvastatin metabolism (eg, by CYP3A) and/or transport (eg, by OATP1B1/SLCO1B1).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2017.</p>\n<p>2. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc; August 2017.</p>\n<p>4. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7041":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider an alternative, non-hormone-based contraceptive in patients receiving cobicistat-containing products.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> US prescribing information states that women should consider an alternative, non-hormone-based contraceptive in combination with cobicistat-containing products.<sup>1,2,3,4</sup> The average ethinyl estradiol AUC and minimum serum concentration were 25% and 44% lower, respectively, in a study of subjects (N=13) receiving ethinyl estradiol/norgestimate with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product.<sup>1</sup><br><br>The mechanism for this interaction is uncertain. Because cobicistat is an inhibitor of CYP3A, CYP2D6, and several uptake and efflux drug transporters,<sup>1</sup> it may be at least partially responsible for alterations in ethinyl estradiol disposition, but the mechanism by which cobicistat could decrease ethinyl estradiol concentrations is not clear. Elvitegravir, another component of the combination product, is characterized as a moderate CYP2C9 inducer,<sup>1</sup> suggesting that it may also be partially responsible for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7042":"<p><b>Title</b> Progestins (Contraceptive) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider an alternative, non-hormone-based contraceptive in patients receiving cobicistat-containing products. The risks and benefits of these products should be carefully considered in light of their potential long-term toxicities (eg, venous thrombosis, insulin resistance, dyslipidemia, hyperkalemia [particularly with drosperinone]), especially in patients with other risk factors. Drospirenone is specifically contraindicated with atazanavir and cobicistat.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> US prescribing information states that women should consider an alternative, non-hormone-based contraceptive in combination with cobicistat-containing products.<sup>1,2,3,4</sup> The average norgestimate AUC was approximately 2.3-fold higher in a study of subjects (N=13) receiving ethinyl estradiol/norgestimate with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product.<sup>1</sup><br><br>The mechanism of this interaction is unclear. Because cobicistat is an inhibitor of CYP3A, CYP2D6, and several uptake and efflux drug transporters,<sup>1</sup> it may be partially responsible for alterations in norgestimate disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2017.</p>\n<p>3. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7043":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Elvitegravir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Elvitegravir may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider the use of an alternative, non-hormone-based contraceptive, in patients treated with elvitegravir-containing products.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> The average ethinyl estradiol AUC and minimum serum concentration (Cmin) were 25% and 44% lower, respectively, in a study of subjects (n=13) receiving ethinyl estradiol/norgestimate together with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.<sup>1,2</sup> According to US prescribing information for elvitegravir/cobicistat/emtricitabine/tenofovir combination products, women should consider using an alternative, non-hormone-based contraceptive during treatment with these products.<sup>1,2</sup> Similarly, US prescribing information for a single-agent elvitegravir product recommends use of an alternative, non-hormone-based contraceptive during treatment.<sup>3</sup><br><br>The mechanism for this interaction is uncertain. Elvitegravir is characterized as a moderate CYP2C9 inducer,<sup>1</sup> suggesting that it may also be at least somewhat responsible for this observed interaction. Cobicistat, which is another component of the combination product, is a known inhibitor of CYP3A, CYP2D6, and several uptake and efflux drug transporters,<sup>1</sup> suggesting that it could be at least somewhat responsible for alterations in ethinyl estradiol disposition, but the mechanism by which cobicistat could decrease ethinyl estradiol concentrations is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7049":"<p><b>Title</b> Tipranavir / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Tipranavir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.</p> \n<p><b>Discussion</b> In a clinical study of 20 healthy volunteers, coadministration of fluconazole (200 mg once, then 100 mg/day for 12 days) with tipranavir/ritonavir (500/200 mg twice daily for 7 days) was associated with a 32% greater tipranavir maximum concentration (Cmax) and 50% greater tipranavir AUC than was seen in historical control subjects not given fluconazole.<sup>1,2</sup> Fluconazole pharmacokinetic variables were minimally altered (less than 10% decrease in Cmax, AUC).<br><br>The mechanism of this interaction has not been investigated, but may at least partly involve fluconazole inhibition of CYP3A mediated tipranavir metabolism. Tipranavir U.S. prescribing information states that fluconazole doses greater than 200 mg/day are not recommended with tipranavir.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. la Porte CJ, Sabo JP, Elgadi M, et al, “Interaction Studies of Tipranavir-Ritonavir With Clarithromycin, Fluconazole, and Rifabutin in Healthy Volunteers,” <i>Antimicrob Agents Chemother</i>, 2009, 53(1):162-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19015362\">[PubMed 19015362]</a></p>\n<p>2. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7050":"<p><b>Title</b> Atazanavir / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Atazanavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for adverse/toxic effects of atazanavir when coadministered with posaconazole.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministration of posaconazole (400 mg orally twice daily for 7 days) increased the average atazanavir (300 mg orally daily for 14 days) maximum concentration (Cmax) and AUC by 2.6 and 3.7 fold, respectively.<sup>1,2</sup> Posaconazole increased atazanavir Cmax and AUC by 1.5 and 2.5 fold, respectively, when given with atazanavir/ritonavir (300/100 mg orally daily for 14 days).<br><br>The mechanism of this interaction is not fully understood. Posaconazole inhibition of CYP3A mediated atazanavir metabolism likely contributed to the observed increases in atazanavir exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Krishna G, Moton A, Ma L, et al, “Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2009, 51(4):437-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19623694\">[PubMed 19623694]</a></p>\n<p>2. Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 6/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7052":"<p><b>Title</b> Ketoconazole (Systemic) / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministraiton of darunavir/ritonavir (400/100 mg twice daily for 7 days) increased ketoconazole (200 mg twice daily for 7 days) maximum concentration (Cmax) and AUC by 2.1 and 3.1 fold, respectively.<sup>1,2</sup> Darunavir Cmax and AUC were also increased, by 21% and 42%, respectively.<br><br>The mechanisms of these interactions have not been investigated. Darunavir and ritonavir may both inhibit CYP3A mediated ketoconazole metabolism. Similarly, ketoconazole may inhibit CYP3A mediated darunavir metabolism. Ketoconazole could also inhibit CYP3A mediated metabolism and/or P-glycoprotein mediated transport of ritonavir, leading to increased ritonavir exposure and potentially further enhanced CYP3A inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sekar VJ, Lefebvre E, De Pauw M, et al, “Pharmacokinetics of Darunavir/Ritonavir and Ketoconazole Following Co-Administration in HIV-Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 2008, 66(2):215-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18460033\">[PubMed 18460033]</a></p>\n<p>2. Prescribing information. Prezista (darunavir). Titusville NJ: Janssen Products, LP, June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7053":"<p><b>Title</b> Itraconazole / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.</p> \n<p><b>Discussion</b> This interaction has not been specifically studied with itraconazole. In a clinical study of healthy volunteers, coadministraiton of darunavir/ritonavir (400/100 mg twice daily for 7 days) increased maximum concentration (Cmax) and AUC of the closely related drug ketoconazole (200 mg twice daily for 7 days) by 2.1 and 3.1 fold, respectively.<sup>1,2</sup> Darunavir Cmax and AUC were also increased, by 21% and 42%, respectively.<br><br>Interactions between ketoconazole or itraconazole and darunavir/ritonavir may occur via several mechanisms. Darunavir and ritonavir may both inhibit CYP3A mediated metabolism of ketoconazole or itraconazole. Similarly, ketoconazole or itraconazole may inhibit CYP3A mediated darunavir metabolism. They also may increase ritonavir exposure via inhibition of its CYP3A mediated metabolism and/or P-glycoprotein mediated efflux, which could in turn further enhance CYP3A inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sekar VJ, Lefebvre E, De Pauw M, et al, “Pharmacokinetics of Darunavir/Ritonavir and Ketoconazole Following Co-Administration in HIV-Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 2008, 66(2):215-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18460033\">[PubMed 18460033]</a></p>\n<p>2. Prescribing information. Prezista (darunavir). Titusville NJ: Janssen Products, LP, June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7055":"<p><b>Title</b> Fosamprenavir / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, ketoconazole dose reductions may be needed for patients receiving ketoconazole doses greater than 400 mg/day.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministraiton of fosamprenavir/ritonavir (700/100 mg twice daily for 4 days) increased ketoconazole maximum concentration (Cmax) and AUC by 25% and 169%, respectively.<sup>1,2</sup> Coadministration of fosamprenavir alone (1.2 g single dose) increased ketoconazole (400 mg single dose) Cmax and AUC by 19% and 44%, respectively.<sup>2</sup> Ketoconazole had no impact on amprenavir pharmacokinetics when given with fosamprenavir/ritonavir, but decreased amprenavir Cmax by 16% and increased amprenavir AUC by 31% when given with fosamprenavir alone.<br><br>The mechanisms of these interactions have not been investigated. Amprenavir and ritonavir may both inhibit CYP3A mediated ketoconazole metabolism. Ketoconazole could also theoretically inhibit CYP3A mediated amprenavir metabolism, but in the presence of ritonavir the impact of this appears to be minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wire MB, Ballow CH, Borland J, et al, “Fosamprenavir Plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, While Amprenavir Exposure Remains Unchanged,” <i>Antimicrob Agents Chemother</i>, 2007, 51(8):2982-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17517848\">[PubMed 17517848]</a></p>\n<p>2. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7056":"<p><b>Title</b> Fosamprenavir / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, itraconazole dose reductions may be needed for patients receiving itraconazole doses greater than 400 mg/day.</p> \n<p><b>Discussion</b> This interaction has not been specifically studied with itraconazole. In a clinical study of healthy volunteers, coadministraiton of fosamprenavir/ritonavir (700/100 mg twice daily for 4 days) increased maximum concentration (Cmax) and AUC of the closely related drug ketoconazole by 25% and 169%, respectively.<sup>1,2</sup> Coadministration of fosamprenavir alone (1.2 g single dose) increased ketoconazole (400 mg single dose) Cmax and AUC by 19% and 44%, respectively.<sup>2</sup> Ketoconazole had no impact on amprenavir pharmacokinetics when given with fosamprenavir/ritonavir, but decreased amprenavir Cmax by 16% and increased amprenavir AUC by 31% when given with fosamprenavir alone.<br><br>The mechanisms of these interactions have not been investigated. Amprenavir and ritonavir may both inhibit CYP3A mediated metabolism of either ketoconazole or itraconazole. Ketoconazole or itraconazole could also theoretically inhibit CYP3A mediated amprenavir metabolism, although this effect may be minimal in the presence of ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wire MB, Ballow CH, Borland J, et al, “Fosamprenavir Plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, While Amprenavir Exposure Remains Unchanged,” <i>Antimicrob Agents Chemother</i>, 2007, 51(8):2982-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17517848\">[PubMed 17517848]</a></p>\n<p>2. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7057":"<p><b>Title</b> Risedronate / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: The nature and severity of this interaction vary between the delayed-release and immediate-release risedronate dosage forms.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of proton pump inhibitors with delayed-release risedronate tablets is not recommended. H2-receptor antagonists (H2RAs) are also expected to interact with the delayed-release ridedronate tablets in a similar manner and are also not recommended, though H2RAs are not expected to interact with immediate-release risedronate tablets. Absorption of both immediate- and delayed-release risedronate tablets may be impaired by concomitant oral intake of antacids.<br><br>Consider carefully the need for proton pump inhibitor therapy in patients being treated with any bisphosphonate derivative, and/or limit the proton pump inhibitor dose/duration of therapy as possible. Older patients and those using higher doses of proton pump inhibitors appear to be at greatest risk.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Both the maximum serum concentration (Cmax) and the AUC of delayed-release risedronate were increased by 60% and 22%, respectively, when coadminstered with esomeprazole.<sup>1</sup> Drugs that increase the pH in the stomach have the potential to accelerate pH-sensitive dissolution of delayed-release risedronate, which is a novel enteric-coated bisphosphonate.<sup>1,2</sup> According to the prescribing information for delayed-release risedronate, antacids, H2-receptor antagonists (H2RAs), and proton pump inhibitors should be avoided with the delayed-release product of risedronate.<sup>1</sup><br><br>According to a cohort study of more than 38,000 alendronate users who were followed for an average of 3.5 years, concurrent use of a proton pump inhibitor (PPI) was associated with a significant decrease in the hip fracture-protection of alendronate.<sup>3</sup> Among non-PPI-users, there was a significant 39% reduction in the risk for hip fracture associated with alendronate use; conversely, among PPI-users, there was only a non-significant 19% reduction in the hip fracture risk with alendronate. Both older patients (particularly those over 70 years of age) and those taking higher doses of a PPI appeared to be at a particularly high risk for decreased alendronate fracture protection.<sup>3</sup> Several analyses of case reports/case series of atypical fractures among bisphophonate users have similarly identified PPI use as a risk factor for the occurrence of these fractures.<sup>4,5,6</sup> Also, a retrospective cohort study found an increased risk of hip fractures and overall fracture risk associated with concurrent PPI use among bisphosphonate users, and an increased risk of hip, spine, or any fracture among all PPI users.<sup>7</sup> These data are somewhat supported by the many studies that have found associations between PPI use and an increased fracture risk,<sup>8,9,10,11,12,13,14</sup> with some even documenting a dose- and/or duration-dependency of the observed risk.<sup>10,12,13,14</sup><br><br>In contrast to these findings, a post-hoc analysis of 2,729 risedronate- and 2,725 placebo-treated subjects, including 8.8% of whom were also receiving an acid-suppressing medication, found no difference in the fracture-protecting effects of risedronate according to PPI use.<sup>15</sup> Several other studies have also failed to find a significant link between PPI use (independent of bisphosphonate use) and the risk for clinical fractures<sup>16,17,18</sup> or changes in bone mineral density.<sup>19</sup> <br>The specific mechanism for any PPI-associated decrease in bisphosphonate protection is uncertain, though several possible mechanisms have been proposed, including both direct effects of PPIs on the bone and more indirect effects (e.g., decreased absorption of calcium, magnesium, vitamin B12, etc.).<sup>3,20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Atelvia (risedronate sodium) delayed-release tablets. Rockaway, NJ: Warner Chilcott (US), LLC, 07/2012.</p>\n<p>2. Kinov P, Boyanov M, “Clinical Utility of Risedronate in Postmenopausal Osteoporosis: Patient Considerations with Delayed-Release Formulation,” <i>Int J Womens Health</i>, 2012, 4L:167-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22532780\">[PubMed 22532780]</a></p>\n<p>3. Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” <i>Arch Intern Med</i>, 2011, Feb 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21321287\">[PubMed 21321287]</a></p>\n<p>4. Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” <i>Endokrynol Pol</i>, 2011, 62(1):84-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365585\">[PubMed 21365585]</a></p>\n<p>5. Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” <i>Bone</i>, 2010, 47(2):169-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20493982\">[PubMed 20493982]</a></p>\n<p>6. Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” <i>Drug Saf</i>, 2009, 32(9):775-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19670917\">[PubMed 19670917]</a></p>\n<p>7. de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” <i>Osteoporos Int</i>, 2009, 20(12):1989-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19333676\">[PubMed 19333676]</a></p>\n<p>8. Ngamruengphong S, Leontiadis GI, Radhi S, et al, “Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies,” <i>Am J Gastroenterol</i>, 2011, Apr 12 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21483462\">[PubMed 21483462]</a></p>\n<p>9. Kwok CS, Yeong JK, Loke YK, “Meta-Analysis: Risk of Fractures with Acid-Suppressing Medication,” <i>Bone</i>, 2011, 48(4):768-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21185417\">[PubMed 21185417]</a></p>\n<p>10. Chiu HF, Huang YW, Chang CC, et al, “Use of Proton Pump Inhibitors Increased the Risk of Hip Fracture: A Population-Based Case-Control Study,” <i>Pharmacoepidemiol Drug Saf</i>, 2010, 19(11):1131-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20872906\">[PubMed 20872906]</a></p>\n<p>11. Gray SL, LaCroix AZ, Larson J, et al, “Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal Women: Results from the Women's Health Initiative,” <i>Arch Intern Med</i>, 2010, 170(9):765-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20458083\">[PubMed 20458083]</a></p>\n<p>12. Corley DA, Kubo A, Zhao W, et al, “Proton Pump Inhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures Among At-Risk Patients,” <i>Gastroenterology</i>, 2010, 139(1):93-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20353792\">[PubMed 20353792]</a></p>\n<p>13. Targownik LE, Lix LM, Metge CJ, et al, “Use of Proton Pump Inhibitors and Risk of Osteoporosis-Related Fractures,” <i>CMAJ</i>, 2008, 179(4):319-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18695179\">[PubMed 18695179]</a></p>\n<p>14. Yang YX, Lewis JD, Epstein S, et al, “Long-Term Proton Pump Inhibitor Therapy and Risk of Hip Fracture,” <i>JAMA</i>, 2006, 296(24):2947-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17190895\">[PubMed 17190895]</a></p>\n<p>15. Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” <i>Osteoporos Int</i>, 2011, Mar 2 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365461\">[PubMed 21365461]</a></p>\n<p>16. Bodmer M, Meier C, Kraenzlin ME, et al, “Proton Pump Inhibitors and Fracture Risk: True Effect or Residual Confounding?” <i>Drug Saf</i>, 2010, 33(10):843-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20812769\">[PubMed 20812769]</a></p>\n<p>17. Pouwels S, Lalmohamed A, Souverein P, et al, “Use of Proton Pump Inhibitors and Risk of Hip/Femur Fracture: A Population-Based Case-Control Study,” <i>Osteoporos Int</i>, 2011, 22(3):903-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585937\">[PubMed 20585937]</a></p>\n<p>18. Kaye JA, Jick H, “Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients Without Major Risk Factors,” <i>Pharmacotherapy</i>, 2008, 28(8):951-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18657011\">[PubMed 18657011]</a></p>\n<p>19. Targownik LE, Lix LM, Leung S, et al, “Proton-Pump Inhibitor Use is Not Associated with Osteoporosis or Accelerated Bone Mineral Density Loss,” <i>Gastroenterology</i>, 2010, 138(3):896-904. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19931262\">[PubMed 19931262]</a></p>\n<p>20. Hyun JJ, Chun HJ, Keum B, et al, “Effect of Omeprazole on the Expression of Transcription Factors in Osteoclasts and Osteoblasts,” <i>Int J Mol Med</i>, 2010, 26(6):877-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21042782\">[PubMed 21042782]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7058":"<p><b>Title</b> Risedronate / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies only to the delayed-release risedronate dosage form. Immediate-release risedronate is not expected to significantly interact with H2-receptor antagonists.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of H2-receptor antagonists (H2RAs) with delayed-release risedronate tablets is not recommended. Proton pump inhibitors (PPIs) are also expected to interact with the delayed-release ridedronate tablets in a similar manner and are also not recommended, and PPIs appear to have a pharmacodynamic interaction with all bisphosphonates (i.e., including immediate-release risedronate). Absorption of both immediate- and delayed-release risedronate tablets may be impaired by concomitant oral intake of antacids. Of note, H2RAs are not expected to interact with immediate-release risedronate tablets.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> Both the maximum serum concentration (Cmax) and the AUC of delayed-release risedronate were increased by 60% and 22%, respectively, when coadminstered with esomeprazole.<sup>1</sup> Drugs that increase the pH in the stomach have the potential to accelerate pH-sensitive dissolution of delayed-release risedronate, which is a novel enteric-coated bisphosphonate.<sup>1,2</sup> According to the prescribing information for delayed-release risedronate, antacids, H2-receptor antagonists (H2RAs), and proton pump inhibitors should be avoided with the delayed-release product of risedronate.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Atelvia (risedronate sodium) delayed-release tablets. Rockaway, NJ: Warner Chilcott (US), LLC, 07/2012.</p>\n<p>2. Kinov P, Boyanov M, “Clinical Utility of Risedronate in Postmenopausal Osteoporosis: Patient Considerations with Delayed-Release Formulation,” <i>Int J Womens Health</i>, 2012, 4L:167-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22532780\">[PubMed 22532780]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7059":"<p><b>Title</b> Sodium Picosulfate / Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Those antibiotics with better activity against colonic bacteria are most likely to have a significant interaction. Antibiotics given via intravenous or oral routes are likely of more concern than those applied topically.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Systemic), Bacampicillin, Bacitracin (Systemic), Bedaquiline, Benzoin, Capreomycin, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Fidaxomicin, Flomoxef, Flucloxacillin, Fosfomycin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Gentian Violet, Hexachlorophene, Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Mafenide, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Neomycin, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxychlorosene, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Oral Inhalation), Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Polymyxin B, Povidone-Iodine (Topical), Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, RifAXIMin, Roxithromycin, Secnidazole, Silver Nitrate, Silver Sulfadiazine, Sparfloxacin, Spiramycin, Streptomycin, Sulfacetamide (Topical), SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Taurolidine, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Aztreonam (Oral Inhalation), Bacitracin (Ophthalmic), Bacitracin (Topical), Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Framycetin, Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), MetroNIDAZOLE (Topical), Mupirocin, Nitrofurazone, Ozenoxacin, Sulfacetamide (Ophthalmic), Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information for the sodium picosulfate/magnesium oxide/anhydrous citric acid product, prior or concurrent use of antibiotics may reduce the efficacy of sodium picosulfate as conversion of sodium picosulfate to its active metabolite, BHPM, is mediated by colonic bacteria.<sup>1</sup> No specific data regarding the interaction are available, and the clinical significance of the interaction is not clear. Considering that inadequate effectiveness can not be monitored prior to the colonoscopy and that inadequate effectiveness may result in the need for another bowel cleansing and another colonoscopy, it seems prudent to consider using an alternative bowel cleansing product in patients with recent or current exposure to antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prepopik (sodium picosulfate, magnesium oxide, and anhydrous citric acid). Parsippany, NJ: Ferring Pharmaceuticals Inc., July 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7060":"<p><b>Title</b> Vitamin K Antagonists / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for changes (increases or decreases are possible) in vitamin K antagonist effectiveness (INR, signs/symptoms of bleeding) when a multivitamin is being started or stopped. The vitamin K and possibly folic acid components are likely to decrease anticoagulant effectiveness, while vitamin E and possibly higher doses of vitamin A may increase anticoagulant effectiveness. The specific effect(s) of individual multivitamins may be better predicted by evaluating the specific amount of these components in the particular multivitamin product. The likelihood of a clinically significant is greater with products containing larger amounts of any of these specific vitamins.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A case report describes 3 warfarin-treated patients who experienced significant changes in their INR following the initiation of multivitamin products containing 25 mcg of vitamin K(1).<sup>1</sup> A study by the same group of authors concluded that patients with lower serum concentrations of vitamin K were more sensitive to the effects of exogenous vitamin K.<sup>2</sup> Of 9 patients with low vitamin K concentrations (10th percentile), all 9 experienced a subtherapeutic INR following initiation of a daily multivitamin containing 25 mcg, and the average INR decreased by 0.51 among this group following multivitamin initiation. Conversely, among the 7 patients with “normal” vitamin K concentrations, only 1 experienced a subtherapeutic INR following multivitamin initiation, and the average INR did not significantly change among this group after initiation of the multivitamin. A review on vitamin K and anticoagulant therapy similarly concluded that patients with higher baseline levels of vitamin K intake are less sensitive to changes in vitamin K intake than patients with lower baseline intake of vitamin K.<sup>3</sup> The degree to which specific vitamin K doses impact anticoagulant therapy is not clear. Studies using vitamin K supplementation to decrease INR variability have reported that vitamin K doses of 150-500 mcg/day given to warfarin-treated patients have necessitated 6-95% increases in warfarin dose.<sup>4,5</sup> Most multivitamin products contain 10-80 mcg per recommended daily dose.<br><br>A warfarin-treated patient exhibited a prolonged prothrombin time (PT) and began to bleed within 2 months of initiating vitamin E therapy (1200 IU/day).<sup>6</sup> A subsequent challenge with 800 IU of vitamin E daily (for 7 weeks) showed a 41% increase in prothrombin time at 7 weeks (changes began at week 4), the development of ecchymoses on extremities, and decreased serum concentrations of blood clotting factors. Warfarin serum concentrations remained unchanged. The patient's coagulation status (including signs of over-anticoagulation) normalized within one week of discontinuing the vitamin E. The prothrombin activity (36 hours postdose) in 3 dicumarol-treated (150 mg single dose) healthy subjects was decreased from 52% to 33% when administered following a 30-day course of vitamin E (42 IU/day).<sup>7</sup> Of note, the author states that “similar results” were obtained using vitamin A (25,000 IU/day) instead of vitamin E, suggesting that higher doses of vitamin A may interact in a similar manner. In contrast, two studies involving 37 patients showed no significant changes in response to warfarin during concomitant administration of vitamin E (doses up to 1200 IU/day).<sup>8,9</sup> The mechanism of this interaction is unknown. One author group has postulated that vitamin E may interfere with the vitamin K-dependent process of clotting factor production.<br><br>The average warfarin dose requirement was non-significantly higher (by 3%) in patients (n=24) who started folic acid supplementation.<sup>10</sup> Similarly, the average S-warfarin clearance was higher following folic acid supplementation. This degree of change is of unlikely significance on its own, but if some patients are more sensitive to this interaction, a clinically meaningful change would be possible. Also, the degree to which this relatively minor interaction impacts the effects of other mulitvitamin components (e.g., vitamin E, vitamin A, vitamin K, etc.) is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kurnik D, Lubetsky A, Loebstein R, et al, “Multivitamin Supplements May Affect Warfarin Anticoagulation in Susceptible Patients,” <i>Ann Pharmacother</i>, 2003, 37(11):1603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14565795\">[PubMed 14565795]</a></p>\n<p>2. Kurnik D, Loebstein R, Rabinovitz H, et al, “Over-the-Counter Vitamin K1-Containing Multivitamin Supplements Disrupt Warfarin Anticoagulation in Vitamin K1-Depleted Patients. A Prospective, Controlled Trial,” <i>Thromb Haemost</i>, 2004, 92(5):1018-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15543329\">[PubMed 15543329]</a></p>\n<p>3. Johnson MA, “Influence of Vitamin K on Anticoagulant Therapy Depends on Vitamin K Status and the Source and Chemical Forms of Vitamin K,” <i>Nutr Rev</i>, 2005, 63(3):91-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15825811\">[PubMed 15825811]</a></p>\n<p>4. Sconce E, Avery P, Wynne H, et al, “Vitamin K Supplementation Can Improve Stability of Anticoagulation for Patients with Unexplained Variability in Response to Warfarin,” <i>Blood</i>, 2007, 109(6):2419-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110451\">[PubMed 17110451]</a></p>\n<p>5. Ford SK, Misita CP, Shilliday BB, et al, “Prospective Study of Supplemental Vitamin K Therapy in Patients on Oral Anticoagulants with Unstable International Normalized Ratios,” <i>J Thromb Thrombolysis</i>, 2007, 24(1):23-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17323135\">[PubMed 17323135]</a></p>\n<p>6. Corrigan JJ and Marcus FI, “Coagulopathy Associated With Vitamin E Ingestion,” <i>JAMA</i>, 1974, 230:1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479598\">[PubMed 4479598]</a></p>\n<p>7. Schrogie JJ, “Coagulopathy and Fat-Soluble Vitamins,” <i>JAMA</i>, 1975, 232:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172961\">[PubMed 1172961]</a></p>\n<p>8. Kim JM and White RH, “Effect of Vitamin E on the Anticoagulant Response to Warfarin,” <i>Am J Cardiol</i>, 1996, 77:545-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=86296604\">[PubMed 86296604]</a></p>\n<p>9. Corrigan JJ and Ulfers LL, “Effect of Vitamin E on Prothrombin Levels in Warfarin-Induced Vitamin K Deficiency,” <i>Am J Clin Nutr</i>, 1981, 34:1701-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7282596\">[PubMed 7282596]</a></p>\n<p>10. Muszkat M, Bialer O, Blotnick S, et al, “Effects of Folic Acid Supplementation on the Pharmacokinetics and Anticoagulant Effect of Warfarin: An Open-Label, Prospective Study of Long-Term Administration in Adults,” <i>Clin Ther</i>, 2010, 32(2):347-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20206792\">[PubMed 20206792]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7061":"<p><b>Title</b> Retinoic Acid Derivatives / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the adverse/toxic effect of Retinoic Acid Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming vitamin A-containing supplements while taking retinoic acid derivatives. If supplements containing vitamin A are used, ensure vitamin A consumption does not exceed the recommended daily allowance of 4,000 to 5,000 units daily due to the risk for vitamin A toxicity.</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Adapalene, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), Bexarotene (Topical), ISOtretinoin (Systemic), Tretinoin (Systemic), Tretinoin (Topical)</p>\n</div> \n<p><b>Discussion</b> Due to the concern for an increased risk of vitamin A toxicity (eg, nausea, vomiting, headache, dizziness, blurred vision, skin and mucous disturbances), prescribing information for retinoic acid derivatives recommends to either strictly avoid all vitamin A supplements<sup>1,2,3,4</sup> or generally avoid vitamin A supplements, and if used, to not exceed the recommended daily allowance of 4,000 to 5,000 units daily.<sup>5</sup> <br><br>The likely mechanism of this potential interaction is retinoid overload resulting from the intake of both the specific retinoid derivative and vitamin A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Soriatane</i> (acitretin) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories Inc; May 2014.</p>\n<p>2. <i>Accutane</i> (isotretinoin) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; January 2010.</p>\n<p>3. Tretinoin [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; December 2011.</p>\n<p>4. <i>Toctino</i> (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2013.</p>\n<p>5. <i>Targretin</i> (bexarotene) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7063":"<p><b>Title</b> Multivitamins/Minerals (with ADEK, Folate, Iron) / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, orlistat may impair the absorption of fat-soluble vitamins. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins.</p> \n<p><b>Discussion</b> Orlistat prescribing information describes reduced absorption of supplemental beta carotene (30%) and vitamin E (60%) associated with its concomitant use.<sup>1</sup> The influence of orlistat on the absorption of other fat soluble vitamins including diet-derived vitamin K or supplemental vitamin A and D has not been demonstrated. As orlistat inhibits gastric and pancreatic lipase, it would seem prudent to anticipate a similar effect on the absorption of these fat soluble vitamins as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7064":"<p><b>Title</b> Multivitamins/Minerals (with ADEK, Folate, Iron) / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Specific recommendations regarding separating the administration of these agents are not defined; however, it would be prudent to separate the administration of these agents by several hours to minimize the potential for a significant interaction. The manufacturer of colesevelam recommends that drugs with a known interaction or uncertain interaction potential should be administered at least 4 hours before colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> In one report, children with hypercholesterolemia (n=5) who had good adherence to treatment with colestipol plus a low-cholesterol diet had significantly decreased vitamin A and vitamin E concentrations.<sup>1</sup> A controlled study of 14 healthy volunteers similarly reported that administration of cholestyramine (12 g) with a vitamin A-containing test meal was associated with an approximate 60% decrease in the expected rise in vitamin A concentrations.<sup>2</sup><br><br>Two case reports and several animal studies support the theory that bile acid sequestrants can impair vitamin D absorption. Both case reports describe patients with prior ileal resections who developed osteomalacia that was attributed to cholestyramine therapy.<sup>3,4</sup> Studies in rats have shown that steatorrhea-inducing doses of cholestyramine impaired vitamin D3 absorption and was associated with altered calcium handling.<sup>5,6</sup> Conversely, two separate long-term clinical studies found that cholestyramine (24 g/d) treatment for up to 7-10 years was not associated with any changes in plasma concentrations of calcium, phosphorous, calcifediol, 25-hydroxy-vitamin D2, or calcitriol.<sup>7,8</sup> Another study in children with hypercholesterolemia found that diet plus colestipol therapy did not negatively impact plasma 25-hydroxycholecalciferol concentrations or calcium metabolism.<sup>1</sup><br><br>Approximately 98% of niacin was bound to colestipol in an in vitro study.<sup>9</sup> A much lower amount (10% to 30%) was bound to cholestyramine,<sup>9</sup> suggesting there may be some differences among the individual bile acid sequestrants.<br><br>This suspected effect of bile acid sequestrants on the absorption of fat-soluble vitamins and possibly niacin could be the result of direct binding of the vitamin by the bile acid-binding resin, resin removal of bile acids that are necessary for fat-soluble vitamin absorption, and/or the impaired absorption could be secondary to drug-induced steatorrhea.<sup>5,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwarz KB, Goldstein PD, Witztum JL, et al, “Fat-Soluble Vitamin Concentrations in Hypercholesterolemic Children Treated with Colestipol,” <i>Pediatrics</i>, 1980, 65(2):243-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7354970\">[PubMed 7354970]</a></p>\n<p>2. Barnard DL, Heaton KW, “Bile Acids and Vitamin A Absorption in Man: The Effects of Two Bile Acid-Binding Agents, Cholestyramine and Lignin,” <i>Gut</i>, 1973, 14(4):316-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4706914\">[PubMed 4706914]</a></p>\n<p>3. Heaton KW, Lever JV, Barnard D, “Osteomalacia Associated with Cholestyramine Therapy for Postileectomy Diarrhea,” <i>Gastroenterology</i>, 1972, 62(4):642-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5020877\">[PubMed 5020877]</a></p>\n<p>4. Compston JE, Horton LW, “Oral 25-Hydroxyvitamin D3 in Treatment of Osteomalacia Associated with Ileal Resection and Cholestyramine Therapy,” <i>Gastroenterology</i>, 1978, 74(5 Pt 1):900-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=640344\">[PubMed 640344]</a></p>\n<p>5. Thompson WG, Thompson GR, “Effect of Cholestyramine on the Absorption of Vitamin D3 and Calcium,” <i>Gut</i>, 1969, 10:717-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4318526\">[PubMed 4318526]</a></p>\n<p>6. Watkins DW, Khalafi R, Cassidy MM, et al, “Alterations in Calcium, Magnesium, Iron, and Zinc Metabolism by Dietary Cholestyramine,” <i>Dig Dis Sci</i>, 1985, 30(5):477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3987479\">[PubMed 3987479]</a></p>\n<p>7. Ismail F, Corder CN, Epstein S, et al, “Effects of Pravastatin and Cholestyramine on Circulating Levels of Parathyroid Hormone and Vitamin D Metabolites,” <i>Clin Ther</i>, 1990, 12(5):427-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2125243\">[PubMed 2125243]</a></p>\n<p>8. Hoogwerf BJ, Hibbard DM, Hunninghake DB, “Effects of Long-Term Cholestyramine Administration on Vitamin D and Parathormone Levels in Middle-Aged Men with Hypercholesterolemia,” <i>J Lab Clin Med</i>, 1992, 119(4):407-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1583392\">[PubMed 1583392]</a></p>\n<p>9. Prescribing information. Niaspan (niacin). Cranbury, NJ: Kos Pharmaceuticals, 12/2010.</p>\n<p>10. West RJ, Lloyd JK, “The Effect of Cholestyramine on Intestinal Absorption,” <i>Gut</i>, 1975, 16:93-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1168607\">[PubMed 1168607]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7065":"<p><b>Title</b> Aluminum Hydroxide / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The significance of this interaction is greater among patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may increase the serum concentration of Aluminum Hydroxide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients with severe renal dysfunction, consider avoiding this combination of agents. Administering agents at least 2 hours apart may help minimize the interaction(s). Monitor for toxic effects of aluminum if a multivitamin is coadministered.</p> \n<p><b>Discussion</b> A small study demonstrated an average 3-fold increase in urinary aluminum excretion when subjects received aluminum hydroxide (900 mg 3 times/day) with concomitant vitamin C (2 g/day).<sup>1</sup> Animal studies have similarly demonstrated increased aluminum concentrations in the liver, brains, and bones of rats given aluminum hydroxide with vitamin C.<sup>2</sup> The mechanism of this interaction is unknown, but has been suggested to be related to the formation of a soluble aluminum-citrate complex.<sup>3</sup><br><br>Several human studies and animal studies have shown that vitamin D enhances aluminum absorption.<sup>4,5,6,7,8,9,10</sup> Given the apparent relationship between vitamin D and aluminum absorption, this risk likely extends to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” <i>Lancet</i>, 1991, 338(8780):1467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1683458\">[PubMed 1683458]</a></p>\n<p>2. Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” <i>Kidney Int</i>, 1991, 39(4):598-601. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2051716\">[PubMed 2051716]</a></p>\n<p>3. Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” <i>Am J Kid Dis</i>, 1991, 17(6):708-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2042654\">[PubMed 2042654]</a></p>\n<p>4. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>, 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>5. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>6. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>7. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>8. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>9. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>10. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7066":"<p><b>Title</b> Cardiac Glycosides / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum calcium concentrations closely and watch for signs and symptoms of cardiac glycoside toxicity (e.g., loss of appetite, nausea and vomiting, etc.) in patients receiving a multivitamin and a cardiac glycoside together. In particular, multivitamins containing vitamin D and/or higher amounts of calcium are those with the highest potential to interact. Hypercalcemia enhances the conduction effects of cardiac glycosides.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Multivitamins containing vitamin D and/or calcium can contribute to hypercalcemia, particularly with higher doses or in high-risk patients. Existing data show that hypercalcemia and cardiac glycosides, such as digoxin, have similar effects on cardiac conduction.<sup>1,2</sup> Consequently, clinically significant adverse effects on cardiac conduction can occur even at therapeutic concentrations of cardiac glycosides in the setting of hypercalcemia.<sup>1</sup> Similarly, cardiac glycosides can exacerbate the negative cardiovascular effects of hypercalcemia. A case report describing an elderly patient who experienced a clinically significant bradyarrhythmia attributed to hypercalcemia (total calcium = 3.0 mmol/L [normal: 2.2-2.5 mmol/L]) and digoxin therapy (digoxin concentration = 1.5 ng/mL [normal/therapeutic: 0.5-2.0 ng/mL]) exemplifies this risk.<sup>1</sup> Other case reports describe cardiac arrhythmias that occurred during concomitant administration of cardiac glycosides and a calcium preparation (primarily IV calcium).<sup>3,4</sup> Though deaths were reported in one citation, a causal relationship was not firmly established.<sup>3</sup><br><br>The mechanism by which hypercalcemia and cardiac glycosides augment one another's effects on conduction involves both the Na+/K+-ATPase and the Ca2+/Na+-antiporter. Cardiac glycosides are known to inhibit Na+/K+-ATPase,<sup>2</sup> increasing intracellular sodium concentrations. This increase in intracellular sodium inhibits action of the Ca2+/Na+-antiporter, which normally transports sodium into the cell as it transports calcium out of the cell. The net effect of inhibiting this antiporter is increased intracellular calcium.<sup>1</sup> Both the cardiac glycosides and excess calcium (i.e., hypercalcemia) decrease the cardiac excitation threshold, shorten the effective refractory period, and increase the refractoriness of the AV node.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vella A, Gerber TC, Hayes DL, et al, “Digoxin, Hypercalcemia, and Cardiac Conduction,” <i>Postgrad Med J</i>, 1999, 75:554-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616693\">[PubMed 10616693]</a> </p>\n<p>2. Kelly RA, Smith TW, “Pharmacological Treatment of Heart Failure,” In: Hardman JG, Limbird LE, Molinoff PB, et al, eds, Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996:809-38.]</p>\n<p>3. Bower Jo and Mengle HAK, “The Additive Effects of Calcium and Digitalis. A Warning With a Report of Two Deaths,” <i>JAMA</i>, 1936, 106:1151.</p>\n<p>4. Nola GT, Pope S, and Harrison DC, “Assessment of the Synergistic Relationship Between Serum Calcium and Digitalis,” <i>Am Heart J</i>, 1970, 79(4):499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5418023\">[PubMed 5418023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7067":"<p><b>Title</b> Calcium Salts / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Diuretics (Thiazide)): The risk for hypercalcemia is likely significantly greater in patients who are also using a thiazide diuretic.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may increase the serum concentration of Calcium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of vitamin D and calcium salts is often recommended, but patients receiving higher supplemental calcium doses together with a multivitamin that contains vitamin D and/or calcium should receive regular monitoring for serum calcium (and phosphate, iPTH, etc., as appropriate) concentrations and for signs/symptoms of hypercalcemia.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> Concurrent use of high doses of calcium-containing products with a multivitamin containing a vitamin D analog and/or calcium may increase the risk for hypercalcemia and other toxicities (e.g., nephrolithiasis, cardiovascular disease, etc.).<sup>1,2,3</sup> It is important to note that the risk for such adverse effects is generally limited to those patients whose calcium and/or vitamin D intake is considerably above dietary reference intake levels, and even with such higher intake, toxicity may not be common. Patients who are also using thiazide diuretics or those with conditions such as renal failure, granulomatous disease, or other conditions associated with hypercalcemia are at greatest risk.<sup>1,2,3</sup><br><br>Vitamin D is an important regulator of calcium absorption and handling, generally working to enhance serum calcium levels.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” <i>Am J Clin Nutr</i>, 2007, 85(1):6-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17209171\">[PubMed 17209171]</a></p>\n<p>2. Peacock M, “Calcium Metabolism in Health and Disease,” <i>Clin J Am Soc Nephrol</i>, 2010, 5 Suppl 1:S23-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20089499\">[PubMed 20089499]</a></p>\n<p>3. Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” <i>Cochrane Database Syst Rev</i>, 2011, (7):CD007470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21735411\">[PubMed 21735411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7068":"<p><b>Title</b> Multivitamins/Minerals (with ADEK, Folate, Iron) / Mineral Oil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, mineral oil may impair the absorption of fat-soluble vitamins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of mineral oil with a multivitamin to minimize the risk for an interaction, though specific recommendations regarding how much to separate administration of these agents are not available. If the multivitamin is being used to increase/maintain concentrations of a specific vitamin or mineral, increased monitoring of serum concentrations may be warranted after initiation of regular mineral oil use.</p> \n<p><b>Discussion</b> The prescribing information for several vitamin D analogs warn that mineral oil may interfere with their absorption.<sup>1,2,3,4</sup> Though specific recommendations regarding administration are not provided in the manufacturer labeling, it would seem prudent to separate the administration of vitamin D, and possibly other fat-soluble vitamins, from mineral oil by several hours to minimize the potential for an interaction. Similarly, the mineral oil prescribing information warns that chronic and abusive use may lead to potentially serious adverse events (e.g., bleeding, metabolic).<sup>5</sup><br><br>In contrast, a published case report describes a 17-year-old female with normal values for prothrombin time, vitamin A and E, alkaline phosphatase, calcium, and phosphorus, despite consuming mineral oil (up to 400 mL/day) for at least 5 months.<sup>6</sup> A study of 25 children who were treated with mineral oil (between meals) for up to 4 months for constipation similarly reported only minimal to moderate effects on serum concentrations of various fat-soluble vitamins.<sup>7</sup> Serum beta-carotene concentrations were reduced by an average of 35%, alpha-tocopherol concentrations were not significantly changed, and serum retinol concentrations were increased by an average of 50%. Others have also questioned the evidence supporting this potential interaction.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, February 2011.</p>\n<p>2. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, March 2007.</p>\n<p>3. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, June 2010. </p>\n<p>4. Product monograph. One-Alpha (alfacalcidol). Thornhill, Ontario:LEO Pharma Inc., March 2010.</p>\n<p>5. Prescribing information. Mineral oil. Greensville, SC: Pharmaceutical Associates, Inc., November 2002.</p>\n<p>6. Gal-Ezer S, Shaoul R, “The Safety of Mineral Oil in the Treatment of Constipation- A Lesson from Prolonged Overdose,” Clin Pediatr, 2006, 45:856-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17041175\">[PubMed 17041175]</a></p>\n<p>7. Clark JH, Russell GJ, Fitzgerald JF, et al, “Serum Beta-Carotene, Retinol, and Alpha-Tocopherol Levels During Mineral Oil Therapy for Constipation,” <i>Am J Dis Child</i>, 1987, 141(11):1210-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3673974\">[PubMed 3673974]</a></p>\n<p>8. Abi-Hanna A, Lake AM, “Constipation and Encopresis in Childhood,” <i>Pediatr Rev</i>, 1998, 19(1):23-30 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9439166\">[PubMed 9439166]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7069":"<p><b>Title</b> Sucralfate / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking multivitamins containing vitamin D. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.</p> \n<p><b>Discussion</b> The prescribing information for the vitamin D analog paricalcitol specifically cautions that excessive and/or chronic concurrent use of aluminum salts and other aluminum-containing products, such as sucralfate, should be avoided due to an increased risk for aluminum accumulation/toxicity.<sup>1</sup> Several human studies and animal studies have shown that vitamin D enhances aluminum absorption.<sup>2,3,4,5,6,7,8</sup> Given the apparent relationship between vitamin D and aluminum absorption, this risk likely extends to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011.</p>\n<p>2. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>., 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>3. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>4. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>5. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>6. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>7. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>8. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7070":"<p><b>Title</b> Vitamin D Analogs / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Multivitamin products with higher doses of vitamin D pose a higher risk than those products with smaller doses of vitamin D.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the adverse/toxic effect of Vitamin D Analogs. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. Multivitamin products with higher doses of vitamin D pose a higher risk than those products with smaller doses of vitamin D.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against combined use with pharmacologic doses of other vitamin D analogs due to the risk for vitamin D toxicity.<sup>1,2,3,4</sup> Though the prescribing information for other vitamin D analogs do not specifically warn against such concurrent use, they do contain warnings regarding the potential for vitamin D toxicity.<sup>5,6,7</sup> Even with relatively low systemic absorption, calcipotriene prescribing information contains cautions about systemic toxicities such as vitamin D toxicity and hypercalcemia.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009.</p>\n<p>2. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010.</p>\n<p>3. Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004.</p>\n<p>4. Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010.</p>\n<p>5. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007.</p>\n<p>6. Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010.</p>\n<p>7. Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7071":"<p><b>Title</b> Multivitamins/Minerals (with ADEK, Folate, Iron) / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of calcium-related toxicities as well as both serum calcium concentrations and response to vitamin D closely in all patients receiving a multivitamin containing vitamin D and/or calcium and a thiazide diuretic.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The product labeling for both ergocalciferol and calcitriol recommend caution with concomitant use of a thiazide diuretic due to the risk of hypercalcemia.<sup>1,2</sup> Studies regarding the effect of thiazide diuretics in combination with either of these agents are relatively lacking. One small study of 6 healthy volunteers fed a low-calcium diet found that those receiving calcitriol differed very little in their response to thiazides from those not receiving calcitriol with regard to measures of calcium balance and vitamin D/parathyroid hormone systems.<sup>3</sup> Thiazides have been shown to decrease urinary calcium excretion in both healthy volunteers and children on long-term calcitriol treatment.<sup>3,4</sup> However, no change in urinary calcium excretion was reported in patients with hypoparathyroidism being treated with vitamin D,<sup>5</sup> leading the study authors to conclude that parathyroid hormone is required for thiazides to have their anti-calciuric effects. This ability to diminish urinary calcium excretion has stimulated interest in using thiazide diuretics with calcitriol to prevent/treat hypocalcemia in certain patients, and one such study reported less hypocalcemia following thyroidectomy in patients receiving calcitriol plus hydrochlorothiazide (n=22) than those receiving placebo (n=20) (4.5% vs. 50%).<sup>6</sup><br><br>Studies examining the effects of thiazide diuretics on calcium and vitamin D metabolism without concurrent calcitriol treatment have reported variable findings. While thiazides have been shown to decrease urinary calcium excretion in healthy volunteers<sup>7,8,9</sup> and patients with idiopathic hypercalciuria,<sup>10</sup> the net effect on calcium concentrations has ranged from increased concentrations<sup>5,7</sup> to no change<sup>8,10</sup> to decreased concentrations.<sup>6,11,12</sup> The reported effects of thiazides on concentrations of endogenous calcitriol and various vitamin D metabolites have been similarly mixed.<sup>7,8,9,10,11,12</sup><br><br>As hypercalcemia is a potential adverse event associated with vitamin D therapy, it would seem prudent to closely monitor serum calcium concentrations in patients receiving concomitant thiazide diuretic therapy.<br><br>Additionally, case reports describe hypercalcemia, and signs and symptoms of the milk-alkali syndrome (including dizziness, weakness, hypercalcemia, metabolic and alkalosis with respiratory compensation), developing in conjunction with concomitant use of thiazide diuretics and calcium supplementation.<sup>13,14,15,16</sup> Thiazide diuretics inhibit the excretion of calcium, as well as bicarbonate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, November 2009. </p>\n<p>2. Prescribing information Rocaltrol (calcitriol). Parsippany, NJ: Validus Pharmaceuticals LLC, July 2009.</p>\n<p>3. Lemann J, Jr., Gray RW, Maierhofer WJ, et al., “Hydrochlorothiazide Inhibits Bone Resorption in Men Despite Experimentally Elevated Serum 1,25-Dihydroxyvitamin D Concentrations,” <i>Kidney Int</i>, 1985, 28:951-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3003445\">[PubMed 3003445]</a></p>\n<p>4. Santos F, Smith MJ,Chan JC, “Hypercalciuria Associated with Long-Term Administration of Calcitriol (1,25-Dihydroxyvitamin D3). Action of Hydrochlorothiazide,” <i>Am J Dis Child</i>, 1986, 140:139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3753816\">[PubMed 3753816]</a></p>\n<p>5. Brickman AS, Massry SG,Coburn JW, “Changes in Serum and Urinary Calcium During Treatment with Hydrochlorothiazide: Studies on Mechanisms,” <i>J Clin Invest</i>, 1972, 51:945-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552338\">[PubMed 4552338]</a></p>\n<p>6. Testa A, Fant V, De Rosa A, et al., “Calcitriol Plus Hydrochlorothiazide Prevents Transient Post-Thyroidectomy Hypocalcemia,” <i>Horm Metab Res</i>, 2006, 38:821-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17163358\">[PubMed 17163358]</a></p>\n<p>7. Krause U, Zielke A, Schmidt-Gayk H, et al., “Direct Tubular Effect on Calcium Retention by Hydrochlorothiazide,” <i>J Endocrinol Invest</i>, 1989, 12:531-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2592738\">[PubMed 2592738]</a></p>\n<p>8. Rejnmark L, Vestergaard P, Heickendorff L, et al., “Effects of Thiazide- and Loop-Diuretics, Alone or in Combination, on Calcitropic Hormones and Biochemical Bone Markers: A Randomized Controlled Study,” <i>J Intern Med</i>, 2001, 250:144-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11489064\">[PubMed 11489064]</a></p>\n<p>9. Riis B,Christiansen C, “Actions of Thiazide on Vitamin D Metabolism: A Controlled Therapeutic Trial in Normal Women Early in the Postmenopause,” <i>Metabolism</i>, 1985, 34:421-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887100\">[PubMed 3887100]</a></p>\n<p>10. Coe FL, Parks JH, Bushinsky DA, et al., “Chlorthalidone Promotes Mineral Retention in Patients with Idiopathic Hypercalciuria,” <i>Kidney Int</i>, 1988, 33:1140-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3404813\">[PubMed 3404813]</a></p>\n<p>11. Nowack R, Hofner MC, Reichel H, et al., “Subacute Effects of Thiazide Administration on Renal Hemodynamics and Calcium Metabolism,” <i>Clin Investig</i>, 1992, 70:686-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1392446\">[PubMed 1392446]</a></p>\n<p>12. Rejnmark L, Vestergaard P, Pedersen AR, et al., “Dose-Effect Relations of Loop- and Thiazide-Diuretics on Calcium Homeostasis: A Randomized, Double-Blinded Latin-Square Multiple Cross-over Study in Postmenopausal Osteopenic Women,” <i>Eur J Clin Invest</i>, 2003, 33:41-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12492451\">[PubMed 12492451]</a></p>\n<p>13. Drinka PJ and Nolten WE, “Hazards of Treating Osteoporosis and Hypertension Concurrently With Calcium, Vitamin D, and Distal Diuretics,” <i>J Am Geriat Soc</i>, 1984, 32(5):405-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6715769\">[PubMed 6715769]</a></p>\n<p>14. Hakim R, Tolis G, Goltzman D, et al, “Severe Hypercalcemia Associated With Hydrochlorothiazide and Calcium Carbonate Therapy,” <i>Can Med Assoc J</i>, 1979, 121(5):591-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=497950\">[PubMed 497950]</a></p>\n<p>15. Gora ML, Seth SK, Bay WH, et al, “Milk-Alkali Syndrome Associated With Use of Cholorothiazide and Calcium Carbonate,” <i>Clin Pharm</i>, 1989, 8(3):227-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27006898\">[PubMed 27006898]</a></p>\n<p>16. Parfitt AM, “Chlorothiazide-Induced Hypercalcemia in Juvenile Osteoporosis and Hyperparathyroidism,” <i>N Engl J Med</i>, 1969, 281(2):55-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5305802\">[PubMed 5305802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7072":"<p><b>Title</b> Agents with Antiplatelet Properties / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a multivitamin that contains vitamin E together with antiplatelet agents.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7073":"<p><b>Title</b> CycloSPORINE (Systemic) / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum cyclosporine concentrations with multivitamin initiation/dose increase.</p> \n<p><b>Discussion</b> In three clinical studies of cyclosporine maintained transplant recipients, antioxidant regimens containing 267-500 mg/day vitamin E were associated with 24-30% lower trough cyclosporine concentrations compared to baseline values or placebo treatment.<sup>1,2,3</sup> All regimens also contained ascorbic acid (500-1000 mg/day), and one contained beta carotene (6 mg/day). The mechanism of this interaction is unknown, and it is unclear whether the observed changes may be attributable to vitamin E or the other supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lake KD, Aaronson KD, Gorman LE, et al, “Effect of Oral Vitamin E and C Therapy on Calcineurin Inhibitor Levels in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(8):990-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16102431\">[PubMed 16102431]</a></p>\n<p>2. Blackhall ML, Fassett RG, Sharman JE, et al, “Effects of Antioxidant Supplementation on Blood Cyclosporine A and Glomerular Filtration Rate in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2005, 20(9):1970-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998657\">[PubMed 15998657]</a></p>\n<p>3. de Vries AP, Oterdoom LH, Gans RO, et al, “Supplementation With Anti-oxidants Vitamin C and E Decreases Cyclosporine A Trough-Levels in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2006, 21(1):231-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115840\">[PubMed 16115840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7074":"<p><b>Title</b> Altretamine / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the therapeutic effect of Altretamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In spite of its beneficial effects on altretamine-associated neurotoxicity, the potential reduction in response duration may warrant consideration of not using multivitamins containing pyridoxine (vitamin B6) with an altretamine/cisplatin regimen.</p> \n<p><b>Discussion</b> An Eastern Cooperative Oncology Group (ECOG) study in 248 patients receiving altretamine and cisplatin for ovarian carcinoma showed both positive and negative effects of adding pyridoxine to the regimen. Pyridoxine use was associated with a significant reduction in neurotoxicity, but concurrent pyridoxine was also one of several factors identified as having an adverse effect on clinical response duration.<sup>1</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiernik PH, Yeap B, Vogl SE, et al, “Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group,” <i>Cancer Invest</i>, 1992, 10(1):1-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1735009\">[PubMed 1735009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7075":"<p><b>Title</b> Barbiturates / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is of most concern with products containing higher doses of pyridoxine (i.e., 80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Barbiturates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of barbiturates in patients receiving concomitant multivitamins, and particularly with any multivitamin containing folic acid and/or high-dose pyridoxine (i.e., 80-200 mg/day).</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Serum phenobarbital concentrations were approximately halved in 5 patients (also receiving chronic phenytoin therapy) following 4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenobarbital metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.<br><br>Levoleucovorin prescribing information cautions that folic acid, and possibly folinic acid (i.e., leucovorin/levoleucovorin), may increase seizure frequency in children treated with phenobarbital, primidone, or phenytoin.<sup>2</sup> Though several reports describe decreases in phenytoin concentrations and therapeutic effectiveness with concurrent folic acid or folinic acid,<sup>3,4,5,6,7,8</sup> there are considerably fewer reports on phenobarbital or primidone. One case series describes an increase in seizure frequency among a group of 26 patients with chronic epilepsy (treated with multiple drugs, including primarily phenobarbital, primidone, and phenytoin) who were given folic acid 5 mg three times daily for 1-3 years.<sup>9</sup> Following addition of folic acid, seizure frequency increased in 50% of patients, though many (22/26) noted an improvement in mental status with folic acid.<br><br>The exact mechanism by which folic acid and/or folinic acid (leucovorin/levoleucovorin) may interact with phenobarbital or primidone is uncertain, but it has been postulated that folates enhance a metabolic pathway that is common to all of these antiepileptic agents (parahydroxylation).<sup>10</sup> In support of this theory, data for phenytoin supports a role for folic acid as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentrations increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>5,6</sup> It is suspected that any leucovorin/levoleucovorin interaction with phenobarbital or primidone would occur via an identical mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p>2. Prescribing information. Levoleucovorin. Irvine, CA: Spectrum Pharmaceuticals, Inc., 2008.</p>\n<p>3. Veldhorst-Janssen NML, Boersma HH, de Krom MCFM, et al, “Oral Tegafur/Folinic Acid Chemotherapy Decreases Phenytoin Efficacy,” <i>Br J Cancer</i>, 2004, 90:745. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14760393\">[PubMed 14760393]</a></p>\n<p>4. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>5. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>6. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>7. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>8. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>9. Reynolds EH, Wales MB, “Effects of Folic Acid on the Mental State and Fit-Frequency of Drug-Treated Epileptic Patients,” <i>Lancet</i>, 1967, 1(7499):1086-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4164775\">[PubMed 4164775]</a></p>\n<p>10. Viukari NMA, “Folic Acid and Anticonvulsants,” <i>Lancet</i>, 1968, 1(7539):980. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4171606\">[PubMed 4171606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7076":"<p><b>Title</b> Fosphenytoin-Phenytoin / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is of most concern with products containing higher doses of pyridoxine (i.e., 80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of phenytoin in patients receiving concomitant multivitamins, and particularly with any multivitamin containing folic acid and/or high-dose pyridoxine (i.e., 80-200 mg/day).</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>1</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1 mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>2,3</sup> while addition of 5 mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>4,5</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>6,7,8</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>1,2,5,9,10</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>2,3,9,10</sup><br><br>In addition, serum phenytoin concentrations were approximately halved in patients (also receiving chronic phenobarbital therapy) following 2-4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>11</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenytoin metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>2. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>3. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>4. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>5. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>6. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>7. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>8. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>9. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>10. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p>11. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentration of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7077":"<p><b>Title</b> Levodopa / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administration of an iron-containing multivitamin and levodopa should be separated by at least 2 hours to minimize the impact of this potential interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated. Also, if levodopa is being used in the absence of a dopa decarboxylase inhibitor (DDI), concomitant use of a multivitamin containing pyridoxine (vitamin B6) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will largely eliminate the risk of this interaction.</p> \n<p><b>Discussion</b> Levodopa AUC decreased by 30% in healthy volunteers and 50% in patients with Parkinson disease, when administered with a single oral dose of ferrous sulfate (325 mg, containing 65 mg elemental iron).<sup>1,2</sup> Carbidopa AUC decreased by 75% in one study.<sup>1</sup> Ferric iron, as exists in the acidic pH of the GI tract, forms a poorly absorbed chelate with both levodopa and carbidopa. The clinical significance of this interaction is unknown.<br><br>Also, the therapeutic effects of levodopa have been abolished in patients receiving concomitant pyridoxine in doses from 5-1000 mg/day.<sup>1,2,3,4,5</sup> When levodopa is administered with carbidopa (a dopa-decarboxylase inhibitor), no such interaction with pyridoxine occurs.<sup>6</sup> Pyridoxine enhances the conversion of levodopa to dopamine by increasing the concentration of a necessary cofactor, pyridoxal-5-phosphate. Excess pyridoxine increases the rate of conversion, and thus decreases the amount of levodopa available to cross the blood-brain barrier, and thus exert its therapeutic, anti-Parkinson effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Campbell NR, Rankine D, Goodridge AE, et al, “Sinemet-Ferrous Sulphate Interaction in Patients With Parkinson’s Disease,” <i>Br J Clin Pharmacol</i>, 1990, 30(4):599-605. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2291872\">[PubMed 2291872]</a></p>\n<p>2. Campbell NR and Hasinoff B, “Ferrous Sulfate Reduces Levodopa Bioavailability: Chelation as a Possible Mechanism,” <i>Clin Pharmacol Ther</i>, 1989, 45(3):220-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2920496\">[PubMed 2920496]</a></p>\n<p>3. Carter AB, “Pyridoxine and Parkinsonism,” <i>Br Med J</i>, 1973, 4:236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4758412\">[PubMed 4758412]</a></p>\n<p>4. Cotzias GC and Papavasiliou PS, “Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa,” <i>JAMA</i>, 1971, 215:1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107638\">[PubMed 5107638]</a></p>\n<p>5. Duvoisin RC, Yahr MD, and Cote LD, “Pyridoxine Reversal of L-Dopa Effects in Parkinsonism,” <i>Trans Am Neurol Ass</i>, 1969, 94:81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5374494\">[PubMed 5374494]</a></p>\n<p>6. Hildick-Smith M, “Pyridoxine in Parkinsonism,” <i>Lancet</i>, 1973, ii:1029.</p>\n<p>7. Yahr MD and Duvoisin RC, “Pyridoxine and Levodopa in the Treatment of Parkinsonism,” <i>JAMA</i>, 1972, 220:861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5067358\">[PubMed 5067358]</a></p>\n<p>8. Papavasiliou PS, Cotzias GC, Duby SE, et al, “Levodopa in Parkinsonism: Potentiation of Central Effects With a Peripheral Inhibitor,” <i>N Engl J Med</i>, 1972, 285:8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4550085\">[PubMed 4550085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7078":"<p><b>Title</b> Raltitrexed / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the therapeutic effect of Raltitrexed. Specifically, the folic acid contained in multivitamins is responsible for this potential interaction. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients should not take folic acid-containing multivitamins immediately prior to or during treatment with raltitrexed. Such concurrent use could significantly impair the effectiveness of raltitrexed.</p> \n<p><b>Discussion</b> Raltitrexed is a folate analogue that inhibits thymidylate synthetase. Administration of a folic acid-containing multivitamin immediately prior to or during treatment with raltitrexed must be avoided as this might interfere with the therapeutic action of raltitrexed.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Tomudex (raltitrexed). Saint-Laurent, Quebec, Canada: Hospira Healthcare Corporation, April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7079":"<p><b>Title</b> Multivitamins/Minerals (with ADEK, Folate, Iron) / Colchicine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to the cyanocobalamin (vitamin B12) component of multivitamins in patients receiving long-term colchicine.</p> \n<p><b>Discussion</b> Several reports describe pernicious anemia and/or vitamin B12 malabsorption in patients receiving colchicine.<sup>1,2,3</sup><br><br>Animal studies suggest that colchicine interferes with the expression of the intrinsic factor-vitamin B12 receptor, contributing to deficient vitamin B12 absorption.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Palopoli J, Waxman J, “Recurrent Aphthous Stomatitis and Vitamin B12 Deficiency,”<i> South Med J</i>, 1990, 83(4):475-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2321075\">[PubMed 2321075]</a></p>\n<p>2. Webb DI, Chodos RB, Mahar CQ, et al, “Mechanism of Vitamin B12 Malabsorption in Patients Receiving Colchicine,” <i>N Engl J Med</i>, 1968, 279(16):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5677718\">[PubMed 5677718]</a></p>\n<p>3. Race TF, Paes IC, Faloon WW, “Intestinal Malabsorption Induced by Oral Colchicine. Comparison with Neomycin and Cathartic Agents,” <i>Am J Med Sci</i>, 1970, 259(1):32-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5416781\">[PubMed 5416781]</a></p>\n<p>4. Polliotti BM, Panigel M, Miller RK, “Free Vitamin B12 and Transcobalamin II-Vitamin B12 Complex Uptake by the Visceral Yolk Sac of the Sprague-Dawley Rat: Effect of Inhibitors,” <i>Reprod Toxicol</i>, 1997, 11(4):617-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241684\">[PubMed 9241684]</a></p>\n<p>5. Ramanujam KS, Seetharam S, Dahms NM, et al, “Functional Expression of Intrinsic Factor-Cobalamin Receptor by Renal Proximal Tubular Epithelial Cells,” <i>J Biol Chem</i>, 1991, 266(20):13135-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1649178\">[PubMed 1649178]</a></p>\n<p>6. Stopa EG, O'Brien R, Katz M, “Effect of Colchicine on Guinea Pig Intrinsic Factor-Vitamin B12 Receptor,” <i>Gastroenterology</i>, 1979, 76(2):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=759260\">[PubMed 759260]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7080":"<p><b>Title</b> Cephalexin / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider administering multivitamins at least 3 hours after cephalexin.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, simultaneous coadministration of zinc sulfate (250 mg single oral dose) with cephalexin (500 mg single oral dose) decreased cephalexin maximum concentration (Cmax) and AUC by 31% and 27%, respectively.<sup>1</sup> Cephalexin Cmax and AUC were decreased by 11% and 18%, respectively, when zinc sulfate was administered 3 hours before cephalexin, but there was no significant alteration of these variables when zinc sulfate was administered 3 hours after cephalexin.<br><br>This interaction may be at least partly attributable to zinc inhibition of PEPT1-mediated active uptake of cephalexin from the gastrointestinal tract.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ding Y, Jia Y, Li F, et al, “The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin,” <i>Br J Clin Pharmacol</i>, 2012, 73(3):422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023069\">[PubMed 22023069]</a></p>\n<p>2. Okamura M, Terada T, Katsura T, et al, “Inhibitory Effect of Zinc on PEPT1-Mediated Transport of Glycylsarcosine and Beta-Lactam Antibiotics in Human Intestinal Cell Line Caco-2,” <i>Pharm Res</i>, 2003, 20(9):1389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14567632\">[PubMed 14567632]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7081":"<p><b>Title</b> Ceftibuten / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Ceftibuten. Specifically, the zinc contained in many multivitamins may decrease ceftibuten absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider administering oral zinc-containing multivitamins at least 3 hours after ceftibuten.</p> \n<p><b>Discussion</b> A study in rats found that concurrent administration of zinc with ceftibuten was associated with 50% inhibition of ceftibuten absorption, resulting in significant decreases in ceftibuten maximum concentration (Cmax) and prolonged time to maximum concentration (Tmax).<sup>1</sup> These results are consistent with the findings of an in vitro study where zinc was shown to inhibit the peptide transporter (PEPT1)-mediated uptake of the cephalosporins ceftibuten and cephradine in cultured cells.<sup>2</sup><br><br>Similarly, in a clinical study of 12 healthy volunteers, simultaneous coadministration of zinc sulfate (250 mg single oral dose) with the cephalosporin cephalexin (500 mg single oral dose), which is similarly dependent on PEPT1-mediated intestinal uptake, decreased cephalexin Cmax and AUC by 31% and 27%, respectively.<sup>3</sup> Cephalexin Cmax and AUC were decreased by 11% and 18%, respectively, when zinc sulfate was administered 3 hours before cephalexin, but there was no significant alteration of these variables when zinc sulfate was administered 3 hours after cephalexin.<br><br>This interaction appears to be at least partly attributable to zinc inhibition of PEPT1-mediated active uptake of ceftibuten from the gastrointestinal tract.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Okamura M, Terada T, Katsura T, et al, “Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats,” <i>Drug Metab Pharmacokinet</i>, 2008, 23(6):464-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19122341\">[PubMed 19122341]</a></p>\n<p>2. Okamura M, Terada T, Katsura T, et al, “Inhibitory Effect of Zinc on PEPT1-Mediated Transport of Glycylsarcosine and Beta-Lactam Antibiotics in Human Intestinal Cell Line Caco-2,” <i>Pharm Res</i>, 2003, 20(9):1389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14567632\">[PubMed 14567632]</a></p>\n<p>3. Ding Y, Jia Y, Li F, et al, “The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin,” <i>Br J Clin Pharmacol</i>, 2012, 73(3):422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023069\">[PubMed 22023069]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7082":"<p><b>Title</b> Deferiprone / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Deferiprone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.</p> \n<p><b>Discussion</b> Deferiprone prescribing information recommends separating administration of deferiprone at least 4 hours from administration of medications or supplements that contain polyvalent cations.<sup>1</sup> Deferiprone chelates iron, with lower affinity for binding copper, aluminum, and zinc. Coadministration of any of these cations, or other polyvalent cations such as magnesium and calcium, with deferiprone could theoretically bind deferiprone in the gastrointestinal tract and limit its systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ferriprox (deferiprone). Rockville, MD: ApoPharma USA, Inc., 10/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7083":"<p><b>Title</b> Eltrombopag / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Eltrombopag. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations (e.g., calcium-, magnesium-, iron-, selenium-, or zinc-containing products).</p> \n<p><b>Discussion</b> The eltrombopag AUC was an average of 70% lower following administration of eltrombopag together with an antacid containing aluminum hydroxide, magnesium carbonate, and sodium alginate.<sup>1,2</sup> Similarly, eltrombopag AUC was an average of 75% lower following administration of eltrombopag with a high-calcium meal.<sup>1</sup> The eltrombopag AUC was 47% lower when administered 2 hours after a high-calcium meal, and the eltrombopag AUC was 20% lower when administered 2 hours before a high-calcium meal.<sup>1</sup><br><br>It is likely that this interaction represents chelation, where the polyvalent cation and eltrombopag bind to one another, forming a nonabsorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. <i>Clin Ther</i>. 2009;31(4):764-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19446149\">[PubMed 19446149]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7084":"<p><b>Title</b> Quinolones / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This applies specifically to orally administered quinolone antibiotics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of oral quinolones if administered with polyvalent cation-containing multivitamins.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> The ability of multivalent cations to reduce the absorption of oral quinolones is well-established. It is believed that the 3-carbonyl and 4-oxo functional groups on the antibiotic forms a chelate with the cations resulting in inactive antimicrobials.<sup>1,2,3</sup> This interaction appears most significant with aluminum and magnesium ions, to a lesser extent with calcium ions, and probably nonexistent with sodium ions. The reduction in quinolone absorption can significantly affect Cmax and percent bioavailability, at times inhibiting the therapeutic effectiveness of the antibiotic. Calcium-containing antacids have been reported to reduce quinolone bioavailability to the following percentages: Ciprofloxacin (59%); levofloxacin (97%); lomefloxacin (98%); and norfloxacin (37%).<sup>4,5,6,7,8,9,10</sup> Calcium acetate has been reported to decrease the AUC of oral ciprofloxacin by 51%.<sup>11</sup> Calcium administration appears to affect the rate, but not the extent, of moxifloxacin absorption.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoffken G, Borner K, Glatzel PD, et al, “Reduced Enteral Absorption of Ciprofloxacin in the Presence of Antacids,” <i>Eur J Clin Microbiol</i>, 1985, 4:345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3160584\">[PubMed 3160584]</a></p>\n<p>2. Schentag JJ, Watson WA, Nix DE, et al, “Time-Dependent Interactions Between Antacids and Quinolone Antibiotics,” <i>Clin Pharmacol Ther</i>, 1988, 43:135.</p>\n<p>3. Shimada J, Shiba K, Oguma T, et al, “Effect of Antacid on Absorption of the Quinolone Lomefloxacin,” <i>Antimicrob Agents Chemother</i>, 1992, 36:1219-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329615\">[PubMed 1329615]</a></p>\n<p>4. Shiba K, Sakai O, Shimada J, et al, “Effects of Antacids, Ferrous Sulphate and Ranitidine on Absorption of DR-3355 in Humans,” <i>Antimicrob Agents Chemother</i>, 1992, 36:2270-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>5. Sahai J, Healey DP, Stotka J, et al, “The Influence of Chronic Administration of Calcium Carbonate on the Bioavailability of Oral Ciprofloxacin,” <i>Br J Clin Pharmacol</i>, 1993, 35:302-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8471407\">[PubMed 8471407]</a></p>\n<p>6. Frost RW, Lettieri JT, Noe A, et al, “Effect of Aluminum Hydroxide and Calcium Carbonate Antacids on Ciprofloxacin Bioavailability,” <i>Clin Pharmacol Ther</i>, 1989, 45:165.</p>\n<p>7. Lehto PL and Kivisto KT, “Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin,” <i>Clin Pharmacol Ther</i>, 1994, 56:477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>8. Nix DE, Wilton JH, Ronald B, et al, “Inhibition of Norfloxacin Absorption by Antacids,” <i>Antimicrob Agents Chemother</i>, 1990, 34:432-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2334155\">[PubMed 2334155]</a></p>\n<p>9. Nix DE, Wilton JH, Schentag JJ, et al, “Inhibition of Norfloxacin Absorption by Antacids and Sucralfate,” <i>Rev Infect Dis</i>, 1989, II(Suppl 5):S1096.</p>\n<p>10. Okhamafe AO, Akerele JO, and Chukuka CS, “Pharmacokinetic Interactions of Norfloxacin With Some Metallic Medicinal Agents,” <i>Int J Pharm</i>, 1991, 68:11-18.</p>\n<p>11. Kays MB, Overholser BR, Mueller BA, et al, “Effects of Sevelamer Hydrochloride and Calcium Acetate on the Oral Bioavailability of Ciprofloxacin,”<i> Am J Kidney Dis</i>, 2003, 42(6):1253-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14655198\">[PubMed 14655198]</a></p>\n<p>12. Staff H, Wandel C, Delesen H, et al, “Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers,” <i>Clin Pharmacokinet</i>, 2001, 40(Suppl 1):27-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352439\">[PubMed 11352439]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7085":"<p><b>Title</b> Tetracyclines / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to use of oral tetracyclines.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Tetracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In general, the coadministration of oral polyvalent cations (i.e., calcium, magnesium, zinc, iron) and oral tetracycline derivatives should be avoided. Interactions may be minimized by administering the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the dose of the oral tetracycline derivative. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Several studies have shown that the absorption/bioavailability of tetracycline, minocycline, doxycycline, and oxytetracycline were significantly reduced by the concurrent use of the polyvalent cations calcium, magnesium, or iron.<sup>1,2,3,4,5,6,7</sup> Similarly, serum concentrations and AUC of the tetracyclines have been shown to be reduced by as much as 40-50% with concurrent ingestion of magnesium and zinc salts.<sup>8,9,10,11</sup><br><br>This interaction is likely the result of formation of a non-absorbable cation-tetracycline complex in the GI tract.<sup>12</sup> Separating the doses of the cation and the tetracycline by 2-4 hours appears to have a minimizing effect on the interaction.<sup>3,4</sup> However, even with the recommended dose separation, use of such a combination may still result in significant decreases in tetracycline derivative absorption.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tetracycline. Sellersville, PA: Teva Pharmaceuticals USA, 6/2009.</p>\n<p>2. Prescribing information. Minocin (minocycline). Cranford, NJ: Triax Pharmaceuticals, LLC, 08/2010.</p>\n<p>3. Prescribing information. Vibramycin (doxycycline). New York, NY: Pfizer Inc, April 2007.</p>\n<p>4. Jung H, Peregrina AA, Rodriguez JM, et al, “The Influence of Coffee with Milk and Tea with Milk on the Bioavailability of Tetracycline,” Biopharm Drug Dispos, 1997, 18(5):459-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9210983\">[PubMed 9210983]</a></p>\n<p>5. Garty M and Hurwitz A, “Effect of Cimetidine and Antacids on Gastrointestinal Absorption of Tetracycline,” <i>Clin Pharmacol Ther</i>, 1980, 28(2):203-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7398187\">[PubMed 7398187]</a></p>\n<p>6. Leyden JJ, “Absorption of Minocycline Hydrochloride and Tetracycline Hydrochloride. Effects of Food, Milk and Iron,” <i>J Am Acad Dermatol</i>, 1985, 12:308-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3838321\">[PubMed 3838321]</a></p>\n<p>7. Neuvonen PJ, Gothoni G, Hackman R, et al, “Interference of Iron With the Absorption of Tetracyclines in Man,” <i>Br Med J</i>, 1970, 4:532. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5483323\">[PubMed 5483323]</a></p>\n<p>8. Healy DP, Dansereau RJ, Dunn AB, et al, “Reduced Tetracycline Bioavailability Caused by Magnesium Aluminum Silicate in Liquid Formulations of Bismuth Subsalicylate,” <i>Ann Pharmacother</i>, 1997, 31(12):1460-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9416381\">[PubMed 9416381]</a></p>\n<p>9. Penttila O, Hurme H, and Neuvonen PJ, “Effect of Zinc Sulphate on the Absorption of Tetracycline and Doxycycline in Man,” <i>Eur J Clin Pharmacol</i>, 1975, 9:131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=786686\">[PubMed 786686]</a></p>\n<p>10. Andersson KE, Bratt L, Dencker H, et al, “Inhibition of Tetracycline Absorption by Zinc,” <i>Eur J Clin Pharmacol</i>, 1976, 10:59.</p>\n<p>11. Mapp RK and McCarthy TJ, “The Effect of Zinc Sulphate and of Bicitropeptide on Tetracycline Absorption,” <i>S Afr Med J</i>, 1976, 50:1829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=996681\">[PubMed 996681]</a></p>\n<p>12. Prescribing information. PhosLo (calcium acetate). Waltham, MA: Fresenius Medical Care North America, 3/2011.</p>\n<p>13. Mattila MJ, Neuvonen PJ, Gothoni G, et al, “Interference of Iron Preparations and Milk With the Absorption of Tetracyclines,” <i>Excerpta Medica Int Congr Series No. 254</i>, 1972. Toxicological Problems of Drug Combinations, 128.</p>\n<p>14. Neuvonen PJ and Penttila O, “Effect of Oral Ferrous Sulphate on the Half-Life of Doxycycline in Man,” <i>Eur J Clin Pharmacol</i>, 1974, 7:361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4607747\">[PubMed 4607747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7086":"<p><b>Title</b> Trientine / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Trientine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The manufacturer of trientine recommends avoiding concurrent administration with oral mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk. Oral iron and trientine administration should be separated by at least 2 hours.</p> \n<p><b>Discussion</b> A case series notes that many of the 20 patients with Wilson's disease treated with trientine became iron deficient, an effect that was particularly common in female patients.<sup>1</sup> This iron deficiency was successfully treated with oral iron supplements given 4 hours apart from trientine doses. The manufacturer of trientine recognizes the potential interaction and recommends avoiding concurrent use with iron supplements or separating administration by at least 2 hours.<sup>2</sup> One Wilson's disease treatment guideline, however, recommends avoiding the combination altogether, noting that the resultant trientine-iron complex is toxic (though this assertion is not referenced or otherwise supported).<sup>3</sup><br><br>An evaluation of patients in the maintenance phase of treatment for Wilson's disease found evidence of a probable interaction between trientine and zinc, but it was reported that the suspected interaction had little effect on treatment response (copper balance).<sup>4</sup> Considering this report and the known ability of trientine to bind other minerals such as copper and iron, caution is warranted regarding combined administration of trientine with other minerals such as zinc (which along with trientine is a common treatment of Wilson's disease) or calcium in accordance with manufacturer recommendations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Walshe JM, “Treatment of Wilson's Disease with Trientine (Triethylene Tetramine) Dihydrochloride,” <i>Lancet</i>, 1982, 1:643-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6121964\">[PubMed 6121964]</a></p>\n<p>2. Prescribing information. Syprine (trientine). West Point, PA: Merck and Co., Inc., May 2007.</p>\n<p>3. Roberts EA, Schlisky ML, “A Practice Guideline on Wilson Disease,” <i>Hepatology</i>, 2003, 37(6):1475-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12774027\">[PubMed 12774027]</a></p>\n<p>4. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al, “Treatment of Wilson's Disease with Zinc: Xi. Interaction with Other Anticopper Agents,” <i>J Am Coll Nutr</i>, 1993, 12:26-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8440814\">[PubMed 8440814]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7087":"<p><b>Title</b> Levothyroxine / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levothyroxine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate the oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours. Concomitant administration should be avoided due to the risk of decreased levothyroxine levels/effects. Separate the doses of the thyroid product and the multivitamins by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if a multivitamin is initiated/dose increased, or increased effects if a multivitamin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Levothyroxine prescribing information describes a possible interaction with ferrous sulfate, cautioning that concurrent use may lead to impaired levothyroxine absorption due to the formation of a ferric-thyroxine complex in the gastrointestinal tract.<sup>1</sup> The potential clinical significance of this interaction is illustrated in a published case report in which a patient with primary hypothyroidism experienced recurrent symptoms of hypothyroidism following the addition of ferrous sulfate to his medication regimen.<sup>2</sup> A subsequent increase in the levothyroxine dose resolved the hypothyroid symptoms, but later discontinuation of the ferrous sulfate led to the appearance of hyperthyroidism symptoms, likely due to the higher levothyroxine dose and removal of the interacting ferrous sulfate. In a study of 14 patients with primary hypothroidism on stable doses of levothyroxine, concurrent use of ferrous sulfate (300 mg daily x 12 weeks) resulted in a significant increase in thyroid stimulating hormone concentrations but no substantial change in free thyroxine index.<sup>3</sup> The addition of ferrous sulfate did result in worsening signs and symptoms of hypothyroidism in 9 of the 14 patients. Based on the mechanism behind this apparent drug-drug interaction, it would seem reasonable to anticipate a similar interaction with concomitant use of other orally administered iron salts (e.g., ferrous gluconate, ferrous fumarate) and levothyroxine.<br><br>TSH significantly increased and both free and total T4 decreased with concurrent administration of calcium carbonate (1200 mg/d of elemental calcium) in a prospective cohort study of 20 patients previously stabilized on levothyroxine.<sup>4</sup> After discontinuation of calcium carbonate, TSH and T4 values returned toward baseline values. Similarly, a study in 8 healthy volunteers reported a 20-25% decrease in levothyroxine absorption associated with concurrent ingestion of calcium carbonate, calcium citrate, and calcium acetate (500 mg of elemental calcium each).<sup>5</sup> Several case reports also describe increases in TSH values and/or decreases in T4 associated with concurrent use of calcium carbonate in patients previously stabilized on levothyroxine.<sup>6,7,8,9,10</sup><br><br>The mechanism of this interaction appears to be due to adsorption of levothyroxine to calcium in the GI tract. An in vitro study confirmed that in acidic conditions, levothyroxine does adsorb to calcium carbonate.<sup>4</sup> Reports that separation of calcium carbonate and levothyroxine administration successfully avoids the interaction<sup>9</sup> lend further support to this as the mechanism. The degree to which other thyroid products are at risk for this interaction is unclear. One analysis has concluded that calcium acetate may be associated with a lower interaction risk than calcium carbonate.<sup>11</sup> In a study of 67 hemodialysis patients receiving levothyroxine together with a phosphate binder, those patients receiving calcium carbonate had significantly higher TSH values than those patients receiving calcium acetate.<sup>11</sup><br><br>In a clinical study of 7 euthyroid, healthy volunteers, simultaneous coadministration of chromium picolinate (1 mg) with levothyroxine (1 mg) decreased the AUC of serum T4 by 17%.<sup>12</sup> The mechanism of this interaction has not been investigated, but may involve formation of an insoluble or poorly-soluble chromium-levothyroxine complex in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Synthroid (levothyroxine). North Chicago, Il: Abbott Laboratories, March 2008.</p>\n<p>2. Shakir KM, Chute JP, Aprill BS, et al, “Ferrous Sulfate-Induced Increase in Requirement for Thyroxine in a Patient with Primary Hypothyroidism,” <i>South Med J</i>, 1997, 90:637-9.</p>\n<p>3. Campbell NR, Hasinoff BB, Stalts H, et al, “Ferrous Sulfate Reduces Thyroxine Efficacy in Patients with Hypothyroidism,” <i>Ann Intern Med</i>, 1992, 117:1010-3.</p>\n<p>4. Singh N, Singh PN, Hershman JM, “Effect of Calcium Carbonate on the Absorption of Levothyroxine,” <i>JAMA</i>, 2000;283:2822-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10838651\">[PubMed 10838651]</a></p>\n<p>5. Zamfirescu I, Carlson HE, “Absorption of Levothyroxine when Coadministered with Various Calcium Formulations,” <i>Thyroid</i>, 2011, 21(5):483-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21595516\">[PubMed 21595516]</a></p>\n<p>6. Singh N, Weisler SL, Hershman JM, “The Acute Effect of Calcium Carbonate on the Intestinal Absorption of Levothyroxine,” <i>Thyroid</i>, 2001;11:967-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11716045\">[PubMed 11716045]</a></p>\n<p>7. Mazokopakis EE, Giannakopoulos TG, Starakis IK, “Interaction Between Levothyroxine and Calcium Carbonate,” <i>Can Fam Physician</i>, 2008, 54(1):39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18208953\">[PubMed 18208953]</a></p>\n<p>8. Csako G, McGriff NJ, Rotman-Pikielny P, et al, “Exaggerated Levothyroxine Malabsorption Due to Calcium Carbonate Supplementation in Gastrointestinal Disorders,” <i>Ann Pharmacother</i>, 2001, 35(12):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11793625\">[PubMed 11793625]</a></p>\n<p>9. Butner LE, Fulco PP, Feldman G, “Calcium Carbonate-Induced Hypothyroidism,” <i>Ann Intern Med</i>, 2000, 132(7):595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10744606\">[PubMed 10744606]</a></p>\n<p>10. Schneyer CR, “Calcium Carbonate and Reduction of Levothyroxine Efficacy,” <i>JAMA</i>, 1998, 279(10):750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9508149\">[PubMed 9508149]</a></p>\n<p>11. Diskin CJ, Stokes TJ, Dansby LM, et al, “Effect of Phosphate Binders Upon TSH and L-Thyroxine Dose in Patients on Thyroid Replacement,” <i>Int Urol Nephrol</i>, 2007;39(2):599-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17216296\">[PubMed 17216296]</a></p>\n<p>12. John-Kalarickal J, Pearlman G and Carlson HE, “New Medications Which Decrease Levothyroxine Absorption,” Thyroid, 2007, 17(9):763-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17725434\">[PubMed 17725434]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7088":"<p><b>Title</b> Amphetamines / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with vitamin C-containing multivitamins as reduced absorption of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Concurrent use of amphetamines with ascorbic acid is expected to decrease the absorption of amphetamines from the GI tract, leading to reduced serum amphetamine concentrations and possibly to reduced efficacy.<sup>1,2</sup><br><br>The prescribing information for some amphetamine products also suggests that ascorbic acid may acidify the urine, resulting in increased urinary excretion of the amphetamine and reduced serum concentrations.<sup>3</sup> Despite this claim, many studies have concluded that ascorbic acid (at doses from 1-2 g administered as single doses or up to four times per day, and including oral or IV) has no significant impact on urinary pH.<sup>4,5,6,7,8,9,10,11</sup> It has also been proposed that the potentially relevant change in urine pH with ascorbic acid reported in a few studies of patients with a UTI<sup>12,13,14,15</sup> is likely the result of inhibition of bacterial urease, making the results more a reflection of decreased alkalinization than any true acidification.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p>3. Prescribing information. Vyvanse (lisdexamfetamine). Wayne, PA: Shire US Inc., June 2013.</p>\n<p>4. Traxer O, Huet B, Poindexter J, et al, “Effect of Ascorbic Acid Consumption on Urinary Stone Risk Factors,” <i>J Urol</i>, 2003, 170(2 Pt 1):397-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853784\">[PubMed 12853784]</a></p>\n<p>5. Baxmann AC, De O G Mendonca C, et al, “Effect of Vitamin C Supplements on Urinary Oxalate and pH in Calcium Stone-Forming Patients,” <i>Kidney Int</i>, 2003, 63(3):1066-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12631089\">[PubMed 12631089]</a></p>\n<p>6. Strom JG Jr, Jun HW, “Effect of Urine pH and Ascorbic Acid on the Rate of Conversion of Methenamine to Formaldehyde,” <i>Biopharm Drug Dispos</i>, 1993, 14(1):61-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8427945\">[PubMed 8427945]</a></p>\n<p>7. Wall I, Tiselius HG, “Long-Term Acidification of Urine in Patients Treated for Infected Renal Stones,” <i>Urol Int</i>, 1990, 45(6):336-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2288050\">[PubMed 2288050]</a></p>\n<p>8. Axelrod DR. “Ascorbic Acid and Urinary pH,” <i>JAMA</i>, 1985, 254(10):1310-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4021006\">[PubMed 4021006]</a></p>\n<p>9. Trang JM, Blanchard J, Conrad KA, et al, “Effect of Dietary Ascorbic Acid Restriction and Supplementation on Urine pH in Elderly Males,” <i>JAMA</i>, 1984, 252(21):2960-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502855\">[PubMed 6502855]</a></p>\n<p>10. Barton CH, Sterling ML, Thomas R, et al, “Ineffectiveness of Intravenous Ascorbic Acid as an Acidifying Agent in Man,” <i>Arch Intern Med</i>, 1981, 141(2):211-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7458517\">[PubMed 7458517]</a></p>\n<p>11. Naccarto DV, Bell CJ, Lamy PP, “Appraisal of Ascorbic Acid for Acidifying the Urine of Methenamine-Treated Geriatric Patients,” <i>J Am Geriatr Soc</i>, 1979, 27(1):34-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32196\">[PubMed 32196]</a></p>\n<p>12. Nahata MC, Cummins BA, McLeod DC, “Effect of Ascorbic Acid on Urine pH,” <i>Am J Hosp Pharm</i>, 1981, 38(1):33, 36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211868\">[PubMed 7211868]</a></p>\n<p>13. Hetey SK, Kleinberg ML, Parker WD, et al, “Effect of Ascorbic Acid on Urine pH in Patients with Injured Spinal Cords,” <i>Am J Hosp Pharm</i>, 1980, 37(2):235-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7361797\">[PubMed 7361797]</a></p>\n<p>14. Nahata MC, Shrimp L, Lampman T, et al, “Effect of Ascorbic Acid on Urine pH in Man,” <i>Am J Hosp Pharm</i>, 1977, 34(11):1234-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22245\">[PubMed 22245]</a></p>\n<p>15. Houston JB, Levy G, “Modification of Drug Biotransformation by Vitamin C in Man,” <i>Nature</i>, 1975, 255(5503):78-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1128674\">[PubMed 1128674]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7089":"<p><b>Title</b> Aspirin / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The impact of aspirin on ascorbic acid absorption has only been demonstrated with aspirin doses 600 mg or greater.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a multivitamin that contains vitamin E together with aspirin.</p> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.<br><br>In addition, several observational and clinical studies, in both healthy volunteers and patients, have shown decreased ascorbate absorption and/or systemic concentrations during aspirin administration (from 600 mg single dose up to 3.9 g/day).<sup>59,60,61,62</sup> In contrast, one week of aspirin (3 g/day) had no effect on plasma ascorbate concentrations in healthy volunteers receiving varying dietary ascorbic acid content.<sup>63</sup><br><br>The mechanism and clinical importance of this interaction are unknown. Aspirin may decrease ascorbate absorption,<sup>59</sup> cause depletion of systemic ascorbate stores (e.g., in the gastric mucosa),<sup>60</sup> or both. Gastric ascorbate stores may be used in the process of neutralizing reactive oxygen species generated during aspirin treatment, which suggests a possible role in mediating the risk of aspirin induced gastric mucosal damage.<sup>64,65,66</sup> Ascorbic acid also may also decrease serum aspirin esterase activity,<sup>67</sup> but the clinical impact of this is likely low based on a study of choline salicylate.<sup>68</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p>59. Basu TK, “Vitamin C-Aspirin Interactions,” <i>Int J Vitam Nutr Res Suppl</i>, 1982, 23:83-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6811490\">[PubMed 6811490]</a></p>\n<p>60. Schulz HU, Schurer M, Krupp S, et al, “Effects of Acetylsalicylic Acid on Ascorbic Acid Concentrations in Plasma, Gastric Mucosa, Gastric Juice and Urine--A Double-Blind Study in Healthy Subjects,” <i>Int J Clin Pharmacol Ther</i>, 2004, 42(9):481-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15487806\">[PubMed 15487806]</a></p>\n<p>61. Sahud MA and Cohen RJ, “Effect of Aspirin Ingestion on Ascorbic-Acid Levels in Rheumatoid Arthritis,” <i>Lancet</i>, 1971, 1(7706):937-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102269\">[PubMed 4102269]</a></p>\n<p>62. Loh HS, Watters K and Wilson CW, “The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings,” <i>J Clin Pharmacol</i>, 1973, 13(11):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4490672\">[PubMed 4490672]</a></p>\n<p>63. Johansson U and Akesson B, “Interaction Between Ascorbic Acid and Acetylsalicylic Acid and Their Effects on Nutritional Status in Man,” <i>Int J Vitam Nutr Res</i>, 1985, 55(2):197-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4040504\">[PubMed 4040504]</a></p>\n<p>64. Pohle T, Brzozowski T, Becker JC, et al, “Role of Reactive Oxygen Metabolites in Aspirin-Induced Gastric Damage in Humans: Gastroprotection by Vitamin C,” <i>Aliment Pharmacol Ther</i>, 2001, 15(5):677-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11328262\">[PubMed 11328262]</a></p>\n<p>65. Konturek PC, Kania J, Hahn EG, et al, “Ascorbic Acid Attenuates Aspirin-Induced Gastric Damage: Role of Inducible Nitric Oxide Synthase,” <i>J Physiol Pharmacol</i>, 2006, 57 Suppl 5:125-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17218764\">[PubMed 17218764]</a></p>\n<p>66. Dammann HG, Saleki M, Torz M, et al, “Effects of Buffered and Plain Acetylsalicylic Acid Formulations With and Without Ascorbic Acid on Gastric Mucosa in Healthy Subjects,” <i>Aliment Pharmacol Ther</i>, 2004, 19(3):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984384\">[PubMed 14984384]</a></p>\n<p>67. Gupta JD, Gruca M and Ablett W, “Effect of Other Drugs and Chemicals on the Degradation of Aspirin in Vitro: Possible Extrapolation to In Vivo Metabolism of Aspirin,” <i>Eur J Drug Metab Pharmacokinet</i>, 1979, 4(2):103-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=488131\">[PubMed 488131]</a></p>\n<p>68. Hansten PD and Hayton WL, “Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration,” <i>J Clin Pharmacol</i>, 1980, 20(5-6 Pt 1):326-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7090":"<p><b>Title</b> Bortezomib / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the therapeutic effect of Bortezomib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy. It is probably unnecessary, though, to advise patients to avoid foods/beverages that contain vitamin C (e.g., citrus fruits, etc.).</p> \n<p><b>Discussion</b> In one study, the addition of plasma from healthy volunteers who were taking vitamin C (1 g/d) was associated with decreased bortezomib-induced multiple myeloma cell death in vitro.<sup>1</sup> In the same study, using a mouse model of human multiple myeloma, vitamin C also interfered with the bortezomib inhibition of multiple myeloma cell growth. In another study, vitamin C inhibited bortezomib-mediated cell death in an endometrial carcinoma cell line.<sup>2</sup> A third in vitro study also reported that vitamin C interfered with bortezomib actions, and reported findings consistent with a direct chemical interaction between ascorbic acid and bortezomib.<sup>3</sup><br><br>In contrast to these findings, other reports describe the use of this combination as part of a regimen used in treatment of patients with multiple myeloma -- one using bortezomib/ascorbic acid/melphalan in newly diagnosed multiple myeloma,<sup>4</sup> and another using arsenic trioxide/bortezomib/ascorbic acid in patients with refractory or relapsed multiple myeloma.<sup>5</sup><br><br>One commentary on the issue emphasized the need for additional data in order to accurately determine the clinical significance of this apparent interaction, particularly given that such an interaction with vitamin C may either protect patients from toxicity or interfere with bortezomib effectiveness.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perrone G, Hideshima T, Ikeda H, et al, “Ascorbic Acid Inhibits Antitumor Activity of Bortezomib in Vivo,” <i>Leukemia</i>, 2009, 23:1679-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19369963\">[PubMed 19369963]</a></p>\n<p>2. Llobet D, Eritja N, Encinas M, et al, “Antioxidants Block Proteasome Inhibitor Function in Endometrial Carcinoma Cells,” <i>Anticancer Drugs</i>, 2008, 19:115-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18176107\">[PubMed 18176107]</a></p>\n<p>3. Zou W, Yue P, Lin N, et al, “Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells,” <i>Clin Cancer Res</i>, 2006, 12:273-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397052\">[PubMed 16397052]</a></p>\n<p>4. Berenson JR, Yellin O, Woytowitz D, et al, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: An Effective and Well-Tolerated Frontline Regimen,” <i>Eur J Haematol</i>, 2009, 82:433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226361\">[PubMed 19226361]</a></p>\n<p>5. Berenson JR, Matous J, Swift RA, et al, “A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” <i>Clin Cancer Res</i>, 2007, 13:1762-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17363530\">[PubMed 17363530]</a></p>\n<p>6. Catley L,Anderson KC, “Velcade and Vitamin C: Too Much of a Good Thing?,” <i>Clin Cancer Res</i>, 2006, 12:3-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397016\">[PubMed 16397016]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7092":"<p><b>Title</b> Ketoconazole (Systemic) / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Indinavir. Indinavir may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole. Additionally, monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.</p> \n<p><b>Discussion</b> In a clinical study summarized in indinavir prescribing information, coadministration of ketoconazole (400 mg daily for 7 days) with a reduced 600 mg adult indinavir dose (3 times daily for 7 days) was associated with 31% and 20% lower indinavir maximum concentration (Cmax) and AUC, respectively, compared to 800 mg indinavir given alone.<sup>1</sup> The minimum indinavir concentration (Cmin), however, was 29% greater with the 600 mg regimen with ketoconazole. A further reduced indinavir dose of 400 mg given with ketoconazole was associated with 56%, 58%, and 27% lower Cmax, AUC, and Cmin, respectively, compared to 800 mg alone.<sup>1</sup> <br><br>Ketoconazole coadministration with indinavir may decrease the rate of indinavir metabolism by CYP3A. Additionally, although clinical data are not available, indinavir is expected to increase ketoconazole concentrations via inhibition of its CYP3A mediated metabolism. The impact of ritonavir coadministraiton on this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7093":"<p><b>Title</b> Itraconazole / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Indinavir. Indinavir may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole. Additionally, monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.</p> \n<p><b>Discussion</b> In a clinical study summarized in indinavir prescribing information, coadministration of itraconazole (200 mg twice daily for 7 days) with a reduced 600 mg adult indinavir dose (3 times daily for 7 days) was associated with a 22% decrease in indinavir maximum concentration, no change in AUC, and a 49% increase in minimum concentration, compared to 800 mg indinavir given alone.<sup>1</sup> <br><br>Itraconazole coadministration with indinavir may decrease the rate of indinavir metabolism by CYP3A. Additionally, although clinical data are not available, indinavir is expected to increase itraconazole concentrations via inhibition of its CYP3A mediated metabolism. The impact of ritonavir coadministraiton on the interaction between itraconazole and indinavir is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7095":"<p><b>Title</b> Lopinavir / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministraiton of lopinavir/ritonavir (400/100 mg twice daily for 16 days) increased ketoconazole (200 mg single dose) AUC by 3 fold, without significantly affecting its maximum concentration (Cmax).<sup>1</sup> Lopinavir Cmax decreased slightly (11% on average) with ketoconazole in this study, but its AUC was unaffected. Additionally, a single published case report describes increases in lopinavir and ritonavir minimum concentration of approximately 70% and 30%, respectively, in a patient receiving combined treatment with ketoconazole (200 mg daily for 14 days) and lopinavir/ritonavir (400/100 mg twice daily).<sup>2</sup><br><br>The mechanisms of these interactions have not been investigated, and the individual contributions of lopinavir and ritonavir to the observed increases in ketoconazole exposure are unknown. Both lopinavir and ritonavir could inhibit CYP3A mediated ketoconazole metabolism. Ketoconazole could also increase ritonavir and lopinavir exposure by inhibiting CYP3A mediated metabolism of either drug, and/or P-glycoprotein mediated efflux of ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, 6/2012.</p>\n<p>2. Boffito M, Bonora S, Sales P, et al, “Ketoconazole and Lopinavir/Ritonavir Coadministration: Boosting Beyond Boosting,” <i>AIDS Res Hum Retroviruses</i>, 2003, 19(10):941-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14585223\">[PubMed 14585223]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7096":"<p><b>Title</b> Itraconazole / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.</p> \n<p><b>Discussion</b> This interaction has not been specifically studied with itraconazole. In a clinical study of 12 healthy volunteers, coadministraiton of lopinavir/ritonavir (400/100 mg twice daily for 16 days) increased the AUC of the closely related drug ketoconazole (200 mg single dose) by 3 fold, without significantly affecting its maximum concentration (Cmax).<sup>1</sup> Lopinavir Cmax decreased slightly (11% on average) with ketoconazole in this study, but its AUC was unaffected.<br><br>The mechanism of this interaction has not been investigated, and the individual contributions of lopinavir and ritonavir to the observed increases in ketoconazole exposure are unknown. Lopinavir and ritonavir could both inhibit CYP3A mediated metabolism of ketoconazole or itraconazole. Ketoconazole or itraconazole could also increase ritonavir and lopinavir exposure by inhibiting CYP3A mediated metabolism of either drug, and/or P-glycoprotein mediated efflux of ritonavir. U.S. prescribing information for lopinavir/ritonavir recommends that the maximum adult dose of either ketoconazole or itraconazole be limited to 200 mg daily in patients treated with lopinavir/ritonavir,<sup>1</sup> and two published case reports describe HIV infected patients in whom the dose-adjusted itraconazole regimen seemed to safely and effectively treat <i>Histoplasma capsulatum</i> infections.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, 6/2012.</p>\n<p>2. Hills-Nieminen C, Hughes CA, Houston S, et al, “Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir,” <i>Ann Pharmacother</i>, 2009, 43(12):2117-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19934385\">[PubMed 19934385]</a></p>\n<p>3. Crommentuyn KM, Mulder JW, Sparidans RW, et al, “Drug-Drug Interaction Between Itraconazole and the Antiretroviral Drug Lopinavir/Ritonavir in an HIV-1-Infected Patient With Disseminated Histoplasmosis,” <i>Clin Infect Dis</i>, 2004, 38(8):e73-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15095234\">[PubMed 15095234]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7098":"<p><b>Title</b> Ketoconazole (Systemic) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.</p> \n<p><b>Discussion</b> The ketoconazole maximum serum concentration (Cmax) and AUC were increased by 1.6- and 3.4-fold, respectively, in a clinical study of 12 subjects who received ritonavir (500 mg every 12 hours for 10 days) with ketoconazole (200 mg daily for 7 days).<sup>1</sup> In several other studies, similar ketoconazole AUC increases (2.2- to 3.1-fold) were seen with coadministration of lower, “boosting” doses of ritonavir (100 mg/day to 200 mg/day).<sup>2,3,4,5</sup> Ritonavir Cmax and AUC have been largely unaffected by ketoconazole in these studies, though some report modest increases (17% to 57%) in ritonavir AUC with ketoconazole.<sup>4,5,6,7</sup><br><br>The presumed primary mechanism of this interaction is ritonavir inhibition of CYP3A-mediated ketoconazole metabolism. Any impact of ketoconazole on ritonavir is likely due to ketoconazole inhibition of the CYP3A-mediated metabolism of ritonavir and/or inhibition of transporter-mediated (e.g., P-glycoprotein) efflux of ritonavir. Despite the apparently small to modest overall impact of ketoconazole on total systemic ritonavir exposure, ketoconazole may significantly enhance ritonavir penetration into the central nervous system (i.e., 2.8-fold greater cerebrospinal fluid concentration and ratio of cerebrospinal fluid concentration to plasma concentration at 4 to 5 hours post dose), an effect that is potentially also the result of inhibition of efflux transporters such as P-glycoprotein.<sup>6</sup> The impact of ketoconazole on ritonavir penetration into other tissues is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; February 2012.</p>\n<p>2. Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. <i>Antimicrob Agents Chemother</i>. 2009;53(2):609-614. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19015329\">[PubMed 19015329]</a></p>\n<p>3. Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. <i>Br J Clin Pharmacol</i>. 2008;66(2):215-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18460033\">[PubMed 18460033]</a></p>\n<p>4. Wire MB, Ballow CH, Borland J, et al. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. <i>Antimicrob Agents Chemother</i>. 2007;51(8):2982-2984. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17517848\">[PubMed 17517848]</a></p>\n<p>5. <i>Viekira Pak</i> (ombitasvir, paritaprevir, ritonavir, dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; December 2014.</p>\n<p>6. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. <i>Clin Pharmacol Ther</i>. 2000;68(6):637-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180024\">[PubMed 11180024]</a></p>\n<p>7. Boffito M, Bonora S, Sales P, et al. Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. <i>AIDS Res Hum Retroviruses</i>. 2003;19(10):941-942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14585223\">[PubMed 14585223]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7099":"<p><b>Title</b> Itraconazole / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.</p> \n<p><b>Discussion</b> This interaction has not been specifically investigated using itraconazole. In a clinical study summarized in ritonavir prescribing information, coadministration of ritonavir (500 mg every 12 hours for 10 days) in 12 subjects increased the maximum concentration (Cmax) and AUC of the closely related drug ketoconazole (200 mg daily for 7 days) by 1.6 and 3.4 fold, respectively.<sup>1</sup> In several published studies, similar ketoconazole AUC increases (2.7-3.1 fold) were seen with coadministration of lower-dose ritonavir (200 mg/day) used to boost exposure of another protease inhibitor (darunavir, fosamprenavir, saquinavir).<sup>2,3,4</sup> Under some circumstances, ketoconazole has caused minor increases in the AUC of ritonavir from lower boosting doses (17-29% on average per two studies), but the clinical impact of this increase is questionable.<sup>4,5,6</sup><br><br>The presumed primary mechanism of this interaction is ritonavir inhibition of CYP3A mediated ketoconazole metabolism. Based on the potential for similar increases in itraconazole exposure, ritonavir prescribing information recommends that the itraconazole adult maximum dose be limited to 200 mg/day in patients receiving ritonavir.<sup>1</sup> The overall pharmacokinetic impact of this dose adjustment is unknown, but two published case reports describe HIV infected patients in whom the dose-adjusted itraconazole regimen seemed to safely and effectively treat <i>Histoplasma capsulatum</i> infections.<sup>7,8</sup> In another case report, a patient receiving a higher itraconazole dose (400 mg/day) with saquinavir/ritonavir was estimated to have itraconazole concentrations in or above the desired therapeutic range at least 27 days after itraconazole discontinuation.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 2/2012.</p>\n<p>2. Kaeser B, Zandt H, Bour F, et al, “Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir,” <i>Antimicrob Agents Chemother</i>, 2009, 53(2):609-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19015329\">[PubMed 19015329]</a></p>\n<p>3. Sekar VJ, Lefebvre E, De Pauw M, et al, “Pharmacokinetics of Darunavir/Ritonavir and Ketoconazole Following Co-Administration in HIV-Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 2008, 66(2):215-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18460033\">[PubMed 18460033]</a></p>\n<p>4. Wire MB, Ballow CH, Borland J, et al, “Fosamprenavir Plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, While Amprenavir Exposure Remains Unchanged,” <i>Antimicrob Agents Chemother</i>, 2007, 51(8):2982-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17517848\">[PubMed 17517848]</a></p>\n<p>5. Khaliq Y, Gallicano K, Venance S, et al, “Effect of Ketoconazole on Ritonavir and Saquinavir Concentrations in Plasma and Cerebrospinal Fluid From Patients Infected With Human Immunodeficiency Virus,” <i>Clin Pharmacol Ther</i>, 2000, 68(6):637-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180024\">[PubMed 11180024]</a></p>\n<p>6. Boffito M, Bonora S, Sales P, et al, “Ketoconazole and Lopinavir/Ritonavir Coadministration: Boosting Beyond Boosting,” <i>AIDS Res Hum Retroviruses</i>, 2003, 19(10):941-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14585223\">[PubMed 14585223]</a></p>\n<p>7. Hills-Nieminen C, Hughes CA, Houston S, et al, “Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir,” <i>Ann Pharmacother</i>, 2009, 43(12):2117-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19934385\">[PubMed 19934385]</a></p>\n<p>8. Crommentuyn KM, Mulder JW, Sparidans RW, et al, “Drug-Drug Interaction Between Itraconazole and the Antiretroviral Drug Lopinavir/Ritonavir in an HIV-1-Infected Patient With Disseminated Histoplasmosis,” <i>Clin Infect Dis</i>, 2004, 38(8):e73-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15095234\">[PubMed 15095234]</a></p>\n<p>9. MacKenzie-Wood AR, Whitfeld MJ and Ray JE, “Itraconazole and HIV Protease Inhibitors: An Important Interaction,” <i>Med J Aust</i>, 1999, 170(1):46-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10026677\">[PubMed 10026677]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}